書籍詳細

第I章 基礎

P.27 掲載の参考文献

• 1. Takahashi N, Takahashi Y, Isobe T et al:Amino acid substitutions in inherited albumin variants from amerindian and japanese populations. Proc Natl Acad Sci USA 1987;84:8001-8005.
  pubmed

• 2. Minghetti PP, Ruffner DE, Kuang WJ et al:Molecular structure of human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4 J Biol Chem 1986;261:6747-6757.
  pubmed

• 3. Law SW and Dugaicyk A:Homology between the primary structure ofα-fetoprotein, deduced from a complete cDNA sequence, and serum albumin. Nature 1981;291:201-205

• 4. Morinaga T, Sasaki M, Wegmann TG et al:Primary structures of humanα-fetoprotein and its mRNA. Proc Natl Acad Sci USA 1983;80:4604-4608.

• 5. Huss K, Madison J, Ishioka N et al:The same substitution, glutamic acid→lysine at position 501, Occurs in three alloalbumins of Asiatic origin:Albumin Vancouver, Birmingham, and Adana. Proc Natl Acad Sci USA 1988;85:6692-6696.

• 6. Dugaiczyk A, Law SW, Dennison QE:Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc Natl Acad Sci USA 1982;79:71-75.

• 7. Sargent TD, Yang M, Banner J:Nucleotide sequence ofcloned rat serum albumin messenger RNA. Proc Natl Acad Sci USA 1981;78:243-246.

• 8. Holowachuk EW, Stoltenborg JK, Reed RG et al:Bovine serum albumin:cDNA and expression. EMBL Data Library, 1991.

• 9. 平山千里, 右田俊介:血漿蛋白質構造・機能・病態. 医歯薬出版, 1979, pp134-147.

• 10. Berde CB, Hudson BS, Simoni RD et al:human serum albumin. Spectroscopic studies of binding and proximity relationships for fatty acids and bilirubin. J. Biol. Chem. 1979;254:391-400.
  pubmed

• 11. Carter DC, He XM, Munson AH et al:Three-dimesional structure of human serum albumin. Scienee 1989;244:1195-1198.

• 12. He XM and Carter DC:Atomic structure and chemistry of human serum albumin. Nature 1992;358:209-215.
  pubmed

• 13. Gonzalez JJ:Analysis of the binding of chlorpheniramine to human serum albumin by spectroscopic techniqes. Chem Biol Interact 1994;91:65-74.

• 14. Jakoby MG 4th, Covey DF Cistola DP:Localization of tolbutamide binding sites on human serum albumin using titration calorimetry and heteronuclear 2-D NMR. Biochemistry 1995;34:8780-8787.
  pubmed

• 15. Gonzalez JJ, Moreno F, Blanco FG:Spectroscopic analysis of the binding of amylobarbitone, secbutobarbitone, pentobarbitone, phenobarbitone and quinalbarbitone to human serum albumin. J Pharm Pharmacol 1995;47:436-441.

• 16. Petersen CE, Ha CE, Harohalli K et al:Mutagenesis studies of throxine binding to human serum albumin defined an important structural characteristic of subdomain 2A. Biochemistry 1997;36:7012-7017.

• 17. Ulton DW, Walle UK, Wall T:Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 1998;50:243-249.

• 18. Ivanov AI, Christodoulou J, Parkinson JA et al:Cisplacin binding sites on human albumin. J Biol Chem 1998;273:14721-14730.
  pubmed

P.38 掲載の参考文献

• 1. Dugaiczyk A, Law SW, Dennison OE:Nucleotide sequence and the encoded amino acids of human serum albumin. Proc Natl Acad Sci USA 1982;79:71-75.
  pubmed

• 2. Minghetti PP, Ruffner DE, Kuang WJ et al:Molecular structure of the human albumin gene is revealed bynucleotide sequence within q11-22 of chromosome 4. J Biol Chem 1986;261:6747-6757.
  pubmed

• 3. Sargent TD, Jagodzinski LL, Yang M et al:Fine structure and evolution of the rat serum albumin gene. Mol Cell Biol 1981;1:871-883.
  pubmed

• 4. Meloun B, Moravek L, Kostka V:Complete amino acid sequence of human serum albumin. FEBS lett 1975;58:134-137.
  pubmed

• 5. Knedel VM:Die doppel-albuminamie, eine neue erbliche proteinanomalie. Blut 1957;3:129-134.

• 6. Winter WP, Weitkamp LR, Rucknagel DL:Amino acid substitution in two identical inherited human serum albumin variants:Albumin Oliphant and albumin Ann Arbor. Biochem 1972;11:889-896.

• 7. Madison J, Galliano M, Watkins S et al:Genetic variants of human serum albumin in Italy:Point mutants and a carboxyl-terminal variant. Proc Natl A cad Sci USA 1994;91:6476-6480.

• 8. Takahashi N, Takahashi Y, Putnam FW:Structural changes and metal binding by proalbumins and other amino-terminal genetic variants of human serum albumin. Proc Natl Acad Sci USA 1987;84:7403-7407.
  pubmed

• 9. Brennan SO, Arai K, Madison J et al:Hypermutability of CpG dinucleotides in the propeptide-encoding sequence of the human albumin gene. Proc Natl Acad Sci USA 1990;87:3909-3913.
  pubmed

• 10. Brennan SO, Owen MC, Boswell DR et al:Circulating proalbumin associated with a variant proteinase inhibitor. Biochim Biophys Acta 1984;802:24-28.
  pubmed

• 11. Watkins S, Madison J, Davis E et al:Adonor splice mutation and a single-base deletion produce two carboxyl-terminal variants of human serum albumin. Proc Natl Acad Sci USA 1991;88:5959-5963.

• 12. Nielsen H, Kragh-Hansen U, Minchiotti L et al:Efrect of genetic variation on the fatty acid-binding properties of human serum albumin and proalbumin. Biochim Biophys A cta 1997;1342:191-204.

• 13. Sunthornthepvarakul T, Angkeow P, Weiss RE et al:An identical message mutation in the albumin gene results in familial dysalbuminemic hyperthyroxinemia in 8 unrelated families. Biochem Biophys Res Commun 1994;202:781-787.

• 14. Petersen CE, Chung-Eun H, Mandel M et al:Expression of a human serum albumin variant with high affinity for thyroxine. Biochem Biophys Res Commun 1995;214:1121-1129.

• 15. Carlson J, Sakamoto Y, Laurell C et al:Alloalbuminemia in Sweden:Structural study and phenotypic distribution of nine albumin variants. Proc Natl Acad Sci USA 1992;89:8225-8229.
  pubmed

• 16. Arai K, Ishioka N, Huss K et al:Identical structural changes in inherited albumin variants from different populations. Proc Natl Acad Sci USA 1989;86:434-438.
  pubmed

• 17. Galliano M, Minchiotti L, Porta F et al:Mutations in genetic variants of human serum albumin fbund in haly. Proc Natl Acad Sci USA 1990;87:8721-8725.

• 18. Rufrner DB, Dugaiczyk A:Splicing mutation in human hereditary analbuminemia. Proc Natl Acad Sci USA 1988;85:2125-2129.

• 19. Watkins S, Madison J, Galliano M et al:Analbuminemia:Three cases resulting from difrerent point mutations in the albumin gene. Proc Natl A cad Sci USA 1994;91:9417-9421.

• 20. Esumi H, Takahashi Y, Sato S et al:Aseven-base-pair deletion in an intron of the albumin gene of analbuminemic rats. Proc Natl Acad Sci USA 1983;80:95-99.

• 21. Sugiyama K, Sugimura T, Esumi H:Defective secretion ofalbumin encoded by exon-skipped mRNA found in aged analbuminemic rat liver. Eur J Cell Biol 1993;61:239-246.
  pubmed

P.44 掲載の参考文献

• 1. Straus DS and Takemoto CD:Effect of dietary protein deviation on insulin-like growth factor (IGF)-I and II, IGF binding protein-2, and serum albumin gene expression in rat. Endocrinology 1990;127:1849-1860.

• 2. Ramadori G, Van Damme J, Rieder H et al:Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988;18:1259-1264.
  pubmed

• 3. Moshage HJ, Kleter BE, van Pelt JF et al:Fibrinogen and albumin synthesis are regulated at the transcriptional level during the acute phase response. Biochim Biophys Acta 1988;950:450-454.
  pubmed

• 4. Brenner DA, Buck M, Feitelberg SP et al:Tumor necrosis factor-alpha inhibits albumin gene expression in amurine model of cachexia. J Clin Invest 1990;85:248-255.

• 5. Sharma RJ, Macallan DC, Sedgwick P et al:Kinetics of endotoxin-induced acute-phase protein gene expression and its modulation by TNF-alpha monoclonal antibody. Am J Physiol 1992;262:R786-R793.
  pubmed

• 6. Tavil AS:Hepatic protein metabolism:basic and applied biochemical and clinical aspects. In:The Liver Annual/4", Elsevier, Amsterdam, 1984, p53-96.

• 7. Okuno M, Moriwaki H, Kato M et al:Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes. Biochem Biophys Res Commun 1995;214:1045-1050.
  pubmed

• 8. Nawa K, Nakamura T, Kumatori A et al:Glucocorticoid-dependent expression ofthe albumin gene in adult rat hepatocytes. J Biol Chem 1986;261:16883-16888.

• 9. Weiner FR, Czaja MJ, Giambrone MA et al:Transcriptional and posttranscriptional efrects of dexamethasone on albumin and procollagen messenger RNAs in murine schistosomiasis. Biochemistry 1987;26:1557-1562.
  pubmed

• 10. Decaux JF, Marcillat O, Pichard AL et al:Glucose-dependent and-independent effect of insulin on gene expression. J Biol Chem 1991;266:3432-3438.
  pubmed

• 11. Wanke IE and Wong NCW:Diabetes mellitus decreases the activity ofthe albumin promoter in vitro. J Biol Chem 1991;266:6068-6072.

• 12. Pietrangelo A and Shafritz DA:Homeostatic regulation of hepatocyte nuclear transcription factor 1 expression in cultured hepatoma cells. Proc Natl Acad Sci 1994;91:182-186.
  pubmed

• 13. Hsu SL, Lin YF, Chou CK:Transcriptional regulation of transferrin and albumin genes by retinoic acid in human hepatoma cell line Hep3B. Biochem J 1992;283:611-615.
  pubmed

• 14. Molina A, Oka T, Munoz SM et al:Vitamin B6 suppresses growth and expression of albumin gene in a human hepatoma cell line HepG2. Nutr Cancer 1997;28:206-211.

• 15. Crespo P, Gonzalez C, Albajar M et al:Downregulation of hepatic albumin mRNA in response to induced hypercholesterolemia in rabbits. Biochim Biophys Acta 1992;1128:77-82.
  pubmed

• 16. Urano Y, Watanabe K, Sakai M et al:The human albumin gene. Characterization of the 5' and 3' flanking regions and the polymorphic gene transcripts. J Biol Chem 1986;261:3244-3251.
  pubmed

• 17. Herbomel P and Yaniv M:The regulation of albumin gene expression in mammals. In:"Tissue Specific Gene Expression". (Renkawitz R ed) . VCH Publishers, New York, 1989, p165-184.

• 18. Babiss LE, Bennett A, Friedman JM et al:DNase I-hypersensitive sites in the 5'-flanking region ofthe rat serum albumin gene:correlation between chromatin structure and transcriptional activity. Proc Natl Acad Sci 1986;83:6504-6508.

• 19. Maire P, Wuarin J, and Schibler U:The role of cis-acting promoter elements in tissue-specific albumin gene expression. Science 1989;244:343-346.
  pubmed

• 20. Herbst RS, Friedman N, Darnell JE Jr. et al:Positive and negative regulatory elements in the mouse albumin enhancer. Proc Natl Acad Sci 1989;86:1553-1557.
  pubmed

• 21. Ogawa A, Yano M, Tsujinaka T et al:Gene expression of albumin and liver-specific nuclear transcription factors in liver of protein-deprived rats. J Nutr 1997;127:1328-1332.
  pubmed

• 22. Yamagata K, Oda N, Kaisaki PJ et al:Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young. Nature 1996;384:455-458.
  pubmed

• 23. Barrera-Hernandez G, Wanke IE, and Wong NC:Effects of diabetes mellitus on hepatocyte nuclear factor 1 decrease albumin gene transcription. J Biol Chem 1996;271:9969-9975.

• 24. Barrera-Hernandez G, Wanke IE, and Wong NC:Phlorizin or vanadate treatment reverses impaired expression of albumin and hepatocyte nuclear factor 1 in diabetic rats. Diabetes 1996;45:1217-1222.
  pubmed

P.54 掲載の参考文献

• 1. Miller LL, Bile WF:Synthesis of all plasma protein fraction except gamma globrin by the liver. J Exp Med 1954;99:125-132.

• 2. Miller LL, Bly CG, Bale WF:Plasma and tissue proteins produced by non-hepatic rat organs as studied with lysine-ε-C. J Exp Med 1954;99:133-153.

• 3. Guillouzo A, Beaumont C, Rumeur EL et al:Nefindings on immunolocalization of albumin in rat hepatocytes. Biol Cell 1982;43:163-172.

• 4. Edwards K, Fleischer B, Drybourne H et al:The distribution of albumin precursor protein and albumin in liver. Biochim Biophys Res Commun 1976;72:310-318.

• 5. Katz J, Rosenfeld S, Sellers AL:Sites of plasma albumin catabolism in the rat. Am J Physiol 1961;200:1301-1306.
  pubmed

• 6. Katz J, Rosenfeld S, Sellers AL:Role of the kidney in plasma albumin catabolism. Am J Physiol 1960;198:814-818.
  pubmed

• 7. Maunsbach AB:Degradetion of albumin by rat kidney lysosomes in vitro. Exper Cell Res 1969;58:464.

• 8. Jeejeebhoy KN, Coghill NF:The measurement of gastrointestinal protein loss by a new method. Gut 1961;2:123-130.
  pubmed

• 9. Gitlin D, Janeway CA, Farr LE:Site of catabolism of serum albumin. Nature 1958;181:181-182.

• 10. Baynes JW, Thorpe SR:Identification of albumin catabolism in the rat. Arch Biochim Biophys 1981;206:372-379.

• 11. Strobel JL, Cady SG, Borg TK et al:Identification of fibroblasts as a major site of albumin catabolism in peripheral tissues. J Biol Chem 1986;15:7879-7994.

• 12. 岩崎雅行:血清アルブミン代謝の統一的把握. 日内会誌 1966;55:22-35.

• 13. 沢田憲志:肝硬変におけるアルブミン代謝日内会誌 1965;54:637-645.

• 14. James WPT, Hay AM:Albumin metabolism:Effect of the nutritional state and the dietary protein intake. J Clin Invest 1968;47:1958-1972.

• 15. Yap SH, Strair RK, Shafritz DA:Effect of a short term fast on the distribution of cytoplasmic albumin messenger ribonucleic acid in rat liver. J Biol Chem 1978;253:4944-4949.

• 16. Rothschild MA, Oratz M, Mongelli J et al:Effect of albumin concentration on albumin synthesis in the perfused liver. Amer J Physiol 1969;216:1127-1130.
  pubmed

• 17. Rothschild MA, Oratz M, Wimer E et al:Studies on albumin synthesis:The effect of dextran and cortisone on albumin metabolism in rabbits studied with albumin-I131. J Clin Invest 1960;40:545-554.

• 18. Rothschild MA, Oratz M, Mongelli J et al:Albumin metabolism in rabbits during gamma globulin infusion. J Lab Clin Med 1965;66:733-740.
  pubmed

• 19. Jefferson LS, Liao WSL, Peavy DE:Diabetes-indused alterations in liver protein synthesis. J Biol Chem 1983;25:1369-1375.

• 20. Broum PC, Papaconstantinou J:Coordinated modulation of albumin synthesis and mRNA levels in cultured hepatoma cell by hydrocortison and cyclic AMP analogs. J Biol Chem 1979;254:9379-9384.

• 21. 湯本泰弘:131 Iアルブミンによる肝疾患のアルブミン代謝の検討. 日消誌 1969;66:917-933.

• 22. Katz J, Sellers AL, Bonorris G et al:Studies on the extravascular albumin of rats. Academic press, New York and London, 1970, p129-154.

• 23. Rothschild MA, Oratz M, Schreiber SS:Serum arbumin. Am J Digest Dis 1969;14:711-744.
  pubmed

• 24. 加藤昌彦, 吉田 貴, 森脇久隆ほか:肝硬変患者の生体内アルブミン代謝動態に及ぼす経口分枝鎖アミノ酸投与の影響. 肝臓 1991;32:692-699.

• 25. Weinbren I, Taggart PI, Glass HI:Edema due to abnormal distribution of protein. Lancet 1965;1:512-513.
  pubmed

• 26. Kooman NA, Geers AB, Kortlandt W et al:Albumin infused in nephrotics. Where does it go? Neth J Med 1985;28:148-152.

P.63 掲載の参考文献

• 1. Miller LL, Bale WF:Synthesis of all plasma protein fractions except gamma globulins by the liver. The use of zone electrophoresis and lysine-ε-C14 to define the plasma proteins synthesized by the isolated perfused liver. J Exp Med 1954;99:125-132.

• 2. Guillouzo A, Beaumont C, LeRumeur E et al:New findings on immunolocalization of albumin in rat hepatocytes. Biol Cell 1982;43:163-172.

• 3. Strobel JL, Cady SG, Borg TK et al:Identification of fibroblasts as a major site of albumin catabolism in peripheral tissues. J Biol Chem 1986;261:7989-7994.

• 4. Merkel C, Bolognesi M, Finucci GF et al:Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatology 1989;9:16-22.

• 5. Corti M-C, Guralnic JM, Salive ME et al:Serum albumin level and physical disability as predictors of mortality in older person. JAMA 1994;272:1036-1042.

• 6. 加藤昌彦, 三輪佳行, 田近正洋ほか:肝硬変患者における血清アルブミン測定法の問題点. JJPEN 1998;20:161-165.

• 7. Sterling K:Serum albumin turnover in laennec's cirrhosis as measured by 131I-tagged albumin. J Clin Invest 1951;30:1238-1242.

• 8. Matthews CME:The theory of tracer experiments with 131I-labelled plasma proteins. Physics Med Biol 1957;2:36-53.

• 9. 加藤昌彦, 吉田貴, 森脇久隆ほか:肝硬変症患者の生体内アルブミン代謝動態に及ぼす経口分枝鎖アミノ酸投与の影響. 肝臓 1991;7:692-699.

• 10. Sogami M, Era S, Nagaoka S et al:High-performance liquid chromatographic studies on non-mercapt mercapt conversion of human serum albumin II. J Chromatography 1985;332:19-27.

• 11. Ozaki I, Motomura M, Setoguchi Y et al:Albumin mRNA expression in human liver diseases and its correlation to serum albumin concentration. Gastroenterol Jpn 1991;26:472-476.
  pubmed

• 12. Kuwahata M, Oka T, Asagi K et al:Efrect of branched-chain amino acids on albumin gene expression in the liver of galactosamine-treated rats. J Clin Biochem 1998;9:209-214.

• 13. Maire P, Wuarin J, Schibler U:The role of cis-acting promoter elements in tissue-specific albumin gene expression. Science 1989;244:343-244.
  pubmed

• 14. Pietrangelo A, Panduro A, Chowdhury JR et al:Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat. J Clin Invest 1992;89:1755-1760.
  pubmed

P.76 掲載の参考文献

• 1. Caraway WT:The scientific development of clinical chemistry to 1948. Clin Chem 1973;19:373-383.

• 2. 佐野紀代子:臨床化学分析II-含窒素成分-第2版, 第5章タンパク質, (斎藤正行, 北村元仕, 丹羽正治 編) 東京化学同人, 東京, 1979, pp154-165.

• 3. Bradley DF et al:Aggregation of bound to polyanions. Proc Natl Acad Sci USA 1959;45:944-952.
  pubmed

• 4. 上野景平:総説. 分析化学における陽イオン界面活性剤の応用. JAPAN ANALYST 1971;20:736-748.

• 5. 岡村研太郎:プロムクレゾールパープルを用いる血清アルブミンの定量. 臨床検査 1974;18:646-650.

• 6. 渡辺富美子:アルブミンと色素の結合反応. 検査と技術 1974;2:28-31.

• 7. Rodkey FL:Direct spectrophotometric determination of albumin in serum. Clin Chem 1965;11:478-487.
  pubmed

• 8. Doumas BT et al:Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 1971;31:87-96.
  pubmed

• 9. Louderback A et al:A new dye-binding technique using bromocresol purple for determination of albumin in serum. Clin Chem 1968;14:793-794.

• 10. Bortholomew RI et al:Spectrophotometric studies and analytical application of the protein error of some pH indicators. Proc Aust Assoc Clin Biochemists 1964;1:64-67.

• 11. Webster D:The immediate reaction between bromcresol green and serum as a measure of albumin content. Clin Chem 1977;23:663-665.
  pubmed

• 12. Webster D:A study of the interaction of bromocresol green with isolated serum globulin fractions. Clin Chim Acta 1974;53:109-115.

• 13. Gusteffson JEC:Improved specificity of serum albumin determination and estemation of"acute phase reactants"by use of the bromocresol green reaction. Clin Chem 1976;22:616-622.

• 14. Bonvicini P et al:Heparin interferes with albumin determination by dye-binding methods. Clin Chem 1979;25:1459-1460.
  pubmed

• 15. 村上恵美子ほか:BCG, BCPのアルブミン, α1-, α2-, β-, γ-グロブリンとの反応性. 衛生検査 1990;39:31-35.

• 16. Doumas BT et al:Serum and urine albumin:a progress report on their measurement and clinical significance. Clin Chim Acta 1997;258:3-20.
  pubmed

• 17. Pinnel AE et al:New autometed dye-binding method for serum albumin determination with bromocresol purple. Clin Chem 1978;24:80-86.

• 18. Bush V et al:Bromocresol purple dye-binding methods underestimate albumin that is carrying covalently bound bilirubin. Clin Chem 1987;33:821-823.
  pubmed

• 19. Beyer C et al:Bromocresol purple dye-binding and immunoturbidimetry for albumin measurement in plasma or serum of patients with renal failure. Clin Chem 1994;40:844-845.
  pubmed

• 20. Mabuchi H et al:Underestimation of serum albumin by bromocresol purple method and a major endogenous ligand in uremia. Clin Chem Acta 1987;167:89-96.

• 21. 村本良三ほか:血清保存中のプロムクレゾールパープル法による血清アルブミン濃度の測定値の上昇に関する検討. 臨床化学 1991;20:13-17.

• 22. Sogami M et al:Resolution of human mercapt-and nonmercapt-albumin by performance liquid chromatography. Int J Pept Protein Res 1984;24:96-103.

• 23. 村本良三:正確度を改善したプロムクレゾールパープル法による血清アルブミン定量法の開発. 臨床化学 1997;26:38-43.

• 24. 村本良三ほか:血清アルブミン測定における新プロムクレゾールパープル法の日常検査法としての有用性. 医学検査 1997;46:823-828.

• 25. Mogensen CE:Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984;310:356-360.
  pubmed

• 26. Association of clinical Biochemists Ltd, News Sheet No. 186 1978;10:October.

• 27. Gendler SM:Albumin. Method in Clinical Chemistry. The C.V. Mosby Company, St Louis, 1987, p1066-1073.

• 28. 岡村研太郎:色素法による血清アルブミンの測定. 検査と技術 1977;5:89-92.

• 29. Tietz NW:Amodel for a comprehensive measurement system in clinical chemistry. Clin Chem 1979;25:833-839.

• 30. Baudner S et al:14項目の血漿蛋白のために設定された新しい標準品 (RPPHS Lot 5). (河合忠, 監訳) 臨床検査機器・試薬 1994;17:465-483.

• 31. Pascucci MW et al:Electroimmunoassay of albumin in human serum:accuracy and longterm prccision. Clin Chem 1983;29:1787-1790.
  pubmed

• 32. 定量検査の精密さ・正確さ評価法標準化ワーキンググループ:定量検査の精密さ・正確さ評価法指針 (JAMT-CEP 1-97) . 医学検査 1997;46:1130-1142.
  Medical*Online

• 33. 久保田浩司ほか (血清アルブミン研究会):血清アルブミン測定試薬BCGの測定上の問題点. 免疫学的測定法との比較及び反応条件の測定値に与える影響について. 臨床化学 1997;27 補冊 3.

• 34. 林 富士夫 ほか (血清アルブミン研究会):アルブミン測定試薬BCPの測定上の問題点. 免疫学的測定法との比較及びヒトメルカプトアルブミンとヒトノンメルカプトアルブミンに対する反応性の相違について. 臨床化学 1997;27 補冊 3.

• 35. 村本良三 ほか (血清アルブミン研究会):アルブミン測定試薬BCGおよびBCPの測定上の問題点の改善案. 臨床化学 1997;27 補冊 3.

• 36. 日本臨床衛生検査技師会:平成9年度日臨技臨床検査精度管理調査報告書. 東京, 1997, p66-71.

• 37. 血清蛋白13項目の日本成人基準範囲-NCCLS DOCUMENT C28-P および国際標準品CRM470による7 施設の共同作業の成績. 臨床病理臨時増刊特集第101号, 東京, 1996, 182-188.

P.86 掲載の参考文献

• 1. Schultze HE, Schonenberger M, Schwich:Uber ein prealbumin des menschilichen serums. Biochem Z 1956;328:267-284.

• 2. Wallace MR, Naylor SL, Lluve-Beckerman-B:Localization ofprealbumin gene to chromosome 18. Biochem Biophys Res Commun 1985;129:753-758.

• 3. Kanda Y, Goodman DS et al:The amino acid sequence of human plasma prealbumin. J Biol Chem 1974;249:6796-6805.
  pubmed

• 4. Peterson PA:Aspects of the metabolism of retinol-binding protein and retionol. Vitam Horm 1974;32:181-214

• 5. Socolow EL, Woeber KA, Purdy RH:Preparation of 125I labeled human serum prealbumin and its metabolism in normal and sick patients. J Clin Invest 1965;44:1600-1609.

• 6. Isshiki H, Akira S, Kishimoto T:Reciprocal expression of NF-IL-6 and C/EBP in hepatocyte. New Biologists 1991;3:63-67.

• 7. 島英明, 岡野裕, 田所節子:べーリング・ネフェロメトリー・アナライザー (BNA) を利用したトランスフェリン, レチノール結合蛋白, プレアルブミン測定の検討. 医学と薬学1994;32:145-153.

• 8. Vatassery GT, Quach HT, smith WE:A sensitive assay of transthyretin (prealbumin) in human cerebrospinal fluid in nanogram amounts by ELISA. Clin Chim Acta 1991;197:19-26.

• 9. Itoh Y, Ichihara K, Kawai T:Serum Protein Standardization Project in Japan:Evaluation of an IFCC Reference Material (RPPHS/CRM470) and Establishment of Reference Intervals. J Clin Lab Anal 1997;11:349-352.

• 10. Ichihara K, Kawai T:Determination of reference intervals for 13 plasma proteins based on CRM470 standards and NCCLS-proposed guideline (C28-p, 1992):(1) A trial to select reference individuals by results of screening tests and application of the maximal likelihood method. J Clin Lab Anal 1995;10:110-117.

• 11. 斎藤憲祐, 市原清志, 河合忠:血清蛋白13項目基準範囲設定のための解析結果. 臨床病理特集. 1996;101:102-206.

• 12. Peterson A, Berg T:The concentration of retinol-binding protein, prealbumin and transferrin in the sera of newly delivered mothers and children of various ages. Scand J Clin Lab Invest 1975;35:569-575.

• 13. Haider M, Haider S:Assesment f protein calorie malnutrition. Clin Chem 1984;24:44-49.

• 14. Spiekerman AM:Proteins used innutritional assessment. Clin Lab Med 1983;13:353-63

• 15. Benson MD:Amyloidosis. In:"The Metabolic and Molecular Bases of Inherited Disease" (7th Ed). MacGraw Hill New York, 1995, p4159-4191.

• 16. Saravia MJ:Transthyretin in familial amyloidopathy;genetic and functional aspects. Adv Neurol 1989;48:189-299.

• 17. Mita S, Maeda S, Shimada K et al:Cloning and sequences analysis of cDNA for human prealbumin. Biochem Biophys Res Commun 1984;124:558-564.
  pubmed

• 18. Mita S, Maeda S, Shimada K et al:Enzymatic amplication of β-globulin genomic sequences and restriction site analysis with familial amylodotic polyneuropathy. J Biochem 1986;100:1215-1222.

• 19. Kishikawa M, Nakanishi T, Shimizu A et al:Simple detection of abnormal transthyretin from patients with familial amyloidotic polyneuropathy by high-performance liquid chromatography/electrospray ionization mass spectrometry using material precipitated with specific antiserum. J Mass Spectro 1996;31;112-114.

第II章 病態

P.99 掲載の参考文献

• 1. 平山千里:血漿蛋白とその異常B:アルブミン新版日本血液学全書8. 血漿蛋白と免疫グロブリン. 新版 日本血液学全書刊行委員会編. 丸善 (株), 東京, 1981, p15-30.

• 2. 古賀俊逸, 平山千里:アルブミンおよびプレアルブミン-病態血漿タンパク質-構造・機能・病態. (平山千里, 右田俊介編) 医歯薬出版, 東京, 1979, p319-329.

• 3. 山本 章, 山村 卓, 横山信治:低アルブミン血症最新医学大辞典 (2版) (後藤稠ら編) 医歯薬出版, 東京, 1996, p1154.

• 4. 大阪大学医学部附属病院中央検査部基準値.

• 5. 武藤泰敏:栄養アセスメントがめざすもの. 機能別による栄養アセスメントの実践. ビジュアル臨床栄養百科2巻. 栄養アセスメント. (岡田正ら編) 小学館, 東京, 1996, p8-26.

• 6. 平山千里:血漿タンパク分画の正常値. (年齢別, 性別変動) 血漿タンパク質-構造・機能・病態. (平山千里, 右田俊介編) 医歯薬出版, 東京, 1979, p239-286.

• 7. 大谷英樹:血清蛋白とその分画 臨床検査ガイド 98. (Medical Practice編集委員会編) 1998, p. 159-165.

• 8. 橋本信也:血清蛋白分画. 総合臨床1998:47:1583-1587.

• 9. Golden MHN, Golden BE, Jackson AA:Albumin and nutritional edema. Lancet 1980;1:114-116.

• 10. Yoshida K, Hirayama C:Clinical evaluation of serum levels of tryptophan in hepatobiliary disease. Clin Chim Acta 1980;101:235-240.
  pubmed

• 11. Yap SH et al:Rate of synthesis of albumin in relation to serum levels of essential amino acids in patients with bacterial overgrowth in the small bowel Eur J Clin Invetst 1974;4:279-284.

• 12. Skillman JJ et al:Improved albumin synthesis in postoperative patients by amino acids. N Engl J Med 1971;295:1037-1040.

• 13. Rothschild MA et al:Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. J Clin Invest 1969;48:344-350.
  pubmed

• 14. Jeeleebhoy KN et al:The acute of effect of ethanol on albumin, fibrinogen and transferrin synthesis in the rat. Biochem J 1972;126:1111-1126.

• 15. Jones EA et al:Protein metabolism in the intestinal stagnent loop syndrome. Gut 1968;9:466-469.

• 16. Wochner RD et al:Direct measurement of the rate of synthesis of plasma protein in control subjects and patients with gastrointestinal protein loss. J Clin Invest 1968;47:971-982.

• 17. Bennhold H, Peters H und Roth E:Uber einen Fall von kompletter Analbuminaemie ohne wesentliche klinische Krankheitszeichen. Verh Dtsch Ges Inn Med 1954;60:630-634.

• 18. Mullen JL et al:Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support. Ann Surg 1980;192:604-613.
  pubmed

• 19. 佐藤 真:胃癌患者の栄養評価に関する臨床的研究-術前栄養状態の計量化による術後合併症発生予測指数の作成. 日外会誌1982;83:66-77.

• 20. 小野寺時夫:消化器癌の非治癒切除・姑息手術に対するTPNの適応と限界. 日外会誌1984;85:1001-1005.

• 21. Corti MC et al:Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 1994;271 (13):1036-1042.

• 22. Herrmann FR et al:Serum albumin level on admission as a predictor of death, length of stays, and readmission. Arc Intern Med 1992;152:125-130.

• 23. Rady MY et al:Clinical characteristics of preoperative hypoalbuminemia predict outcome of cardiovascular surgery. JPEN 1997;21:81-90.
  pubmed

• 24. Friedenberg F et al:Serum albumin is predictive of 30-day survival afterpercutaneous endoscopic gastrotomy. JPEN 1997;21:72-74.

P.107 掲載の参考文献

• 1. Naber THJ, Schermer T, de Bree A et al:Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications. Am J Clin Nutr 1997;66:1232-1239.

• 2. Wellcome Trust Working Party:Classification of infantile malnutrition. Lancet 1970;2:302-303

• 3. Young VR, Marchini JS:Mechanisms and nutritional significance of metabolic responses to altered intakes of protein and amino acids, with reference to nutritional adaptation in humans. Am J Clin Nutr 1990;51:270-289.
  pubmed

• 4. Torun B, Chew F:Protein-Energy Malnutrition. In:Modern Nutrition in health and disease 2 (8th Ed). (Shils ME, Olson JA, Shike M eds), Lea&Febiger, Philadelphia, 1994, p950-976.

• 5. Tomkins AM, Garlick PJ, Schofield WN et al:The combined effects of infection and malnutrition on protein metabolism in children. Clin Sci 1983;65:313-324.
  pubmed

• 6. Baltzan MA, Shoker AS, Baltzan RB:Protein malnutrition and decreased protein turnover in chronic renal allograft failure. Clin Nephrol 1997;47:112-116.
  pubmed

• 7. Kirsch R, Firth L, Black E et al:Regulation of albumin synthesis and catabolism by alteration of dietary protein. Nature 1968;217:578-579.

• 8. Morlese J, Forrester T, Badaloo A et al:Albumin kinetics in edematous and non-edematous protein-energy malnourished children. FASEB J 1996;10:A813.

• 9. Manary M, Brewster DR, Broadhead RL et al:Protein metabolism in children with edematous malnutrition and acute lower respiratory infection. Am J Clin Nutr 1997;65:1005-1010.
  pubmed

• 10. Ogawa A, Yano M, Tsujinaka T et al:Gene expression of albumin and liver-specific nuclear transcription factors in liver of protein-deprived rats. J Nutr 1997;127:1328-1332.
  pubmed

• 11. Walter SJ, Shore AC:Effect of potassium depletion on renal tubular function in the rats. Clin Sci 1988;75:621-628.
  pubmed

• 12. Blackburn GL, Bistrian BR, Maini BS:Nutritional and metabolic assessment of the hospitalized patient. JPEN 1977;1:11-22.
  pubmed

• 13. Kaminski MV, Jeejeebhoy KN:Modern clinical Nutrition. Part 1 Nutritional assessment-Diagnosis of malnutrition and selection of therapy. Amer J Intrav Ther Clin Nutr 1979;June-July:31-50.

• 14. Buzby GP, Williford WO, Peterson OL et al:A randomized clinical trial of total parenteral nutrition in malnourished surgical patients:the rationale and impact of previous clinical trials and pilot study on protocol design. Am J Clin Nutr 1988;47:357-365.

• 15. 沖田美佐子:免疫能からみた栄養評価. 臨床栄養1995;86:470-475.

P.114 掲載の参考文献

• 1. 岩佐正人:食道癌患者の栄養評価に関する臨床的研究-特に栄養評価指数 (nutritional assessment index, NAI) の有用性について. 日本外科学雑誌1983;84:1031-1041.

• 2. Chlebowski RT, Grosvenor MB, Bernhard NH et al:Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989;84:1288-1293.
  pubmed

• 3. Guenter P, Muurahainen N, Simons G et al:Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993;6:1130-1138.
  pubmed

• 4. Gosling P, Sutcliffe AJ:Proteinuria following trauma. Ann Clin Biochem 1986;23:681-685.
  pubmed

• 5. Halliwell B:Albumin:an important extracellular antioxident?Biochem Pharmacol 1988;37:569-571.

• 6. Peters T Jr.:Clinical aspects:albumin in medicine. in:All About Albumin. (Peters T Jr. ed.), Academic Press, New York, 1996, p281.

• 7. Christou NV:Predicting septic related mortality of the individual surgical patient based on admission host-defence measurements. Can J Surg l 986;29:424-428.

• 8. Randle NW, Hubert-Hartmann K, Mulherna LC:Serum albumin levels:Relationship to length of hospital stay. Hosp Pharm 1984;19:802-807.

• 9. Ching N, Grossi CE, Angers J et al:The outcome of surgical treatment as related to the response of serum albumin level to nutritional support. Surg Gynecol Obstet 1980;151:199-202.

• 10. Brown RO, Bradley JE, Bekemeyer WB et al:Effect of albumin supplementation during parental nutrition on hospital mortality. Crit Care Med 1988;16:1177-1182.

• 11. Brinson RR, Kolts BE:Hypoalbuminemia as an indicator of diarrheal incidence in critically ill patients. Crit Care Med 1987;15:506-509.
  pubmed

• 12. Ford EG, Jennings M, Andrassy RI:Serum albumin (oncotic pressure) correlates with enteric feeding tolerance in the pediatric surgical patient. J Ped Surg 1987;22:597-599.

• 13. Andrassy RJ, Durt ED:Albumin:use in nutrition and support. Nutr Clin Pract 1988;3:226-229.

• 14. Dawidson IJ, Willms C, Sandor ZF et al:Lactated Ringer's solution versus 3% albumin for resuscitation of a lethal intestinal ischemic shock in rats. Crit Care Med 1990;18:60-66.
  pubmed

• 15. Deitch EA, Xu D QIL, Berg RD:Bacterial translocation from the gut impairs systemic immunity. surgery 1991;109:269-276.

• 16. Foley EF, Borlase BC, Dzik WH et al:Albumin supplementation in the critically ill. A prospective, randomized trial. Arch Surg 1990;125:739-742.
  pubmed

• 17. Perlmutter DH, Dinarello CA, Punsal PI et al:Cathectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 1986;78:1349-1354.
  pubmed

• 18. Andus T, Gerger T, Hirano T et al:Actin of recombinant human interleukin 6, interleukin 1β and tumor necrosis factor α on the mRNA induction of acute phase protein. Eur J Immunol 1988;18:739-746.

• 19. Machlin LJ, Bendick A:Free radical tissue damage:protective role of antioxidant nutrients. FASEB J 1987;1:441-445.

• 20. Gey LF, Brubacher GB, Stohelin HB:Plasma levels of antioxidant vitamins in relation to ischemic heart desease and cancer. Am J Clin Nutr 1987;45:1368-1377.

• 21. Dworkin BM, Wormser GP, Axelrod F et al:Dietary intake in patients with acquired immunodeficiency syndrome (AIDS), patients with AIDS-related complex, and serologically positive human immunodeficiency virus patients. Correlations with nutritional status. JPEN 1990;14:605-609.
  pubmed

• 22. Cirasino L, Landonio G, Imbriani M:Hypoalbuminemia in human immunodeficiency virus infection:Causes and possible prognostic value. J Parent Enter Nutr 1993;17:101-102.

• 23. Darne B, Ducimetiere P, Guize L:Serum albumin and mortality. Lancet 1990;335:350-351.

• 24. Biolo G, Toigo G, Ociocchi B et al:Metabolic response to injury and sepsis:Changes in protein metabolism. Nutrition 1997;13:525-575.

P.123 掲載の参考文献

• 1. 標葉隆三郎, 森昌造:癌悪液質と蛋白代謝, 悪液質. (漆崎一郎編) 先端医学社, 東京, 1993, p30-35.

• 2. 標葉隆三郎, 西平哲郎:癌悪液質と栄養管理. Practical Oncology I 994;7:12-14.

• 3. Drott C, Svaninger G, Lundholm K:Increased urinary excretion of cortisol and cathecholamines in malnutished cancer patients. Ann Surg 1996;208:645-650.

• 4. Knox LS, Crosby LO, Feurer ID:Energy expenditure in malnourished cancer patients. Ann Surg 1983; 197:152-162.
  pubmed

• 5. Tayek JA:Nutritional and biolochemical aspects of the cancer patients. Nutritional Oncology (Herber D, Blackburn GL, W. Go Vay Ling eds.), Academic Press, San Diego, 1999, 519-536.

• 6. Plumb JA, Fearon KC, Carter KB et al:Energy expenditure and protein synthesis in an animal model of cancer cachexia. Clinical Nutrition 1991;10:23-29.

• 7. Luketich JD, Mullen JL, Feurer ID et al:Ablation of abnormal energy expediture by curative tumor resection. Arch Surg 1990;125:337-341.

• 8. Hyltander A, Drott C, Korner U et al:Elevated energy expenditure in cancer patients with solid tumors. Eur J Cancer 1991;27:9-15.
  pubmed

• 9. Fredrix EWH, Soeters PB, Wouters EFM et al:Effect of different tumor types on resting expenditure. Cancer Res 1991;51:6138-6141.

• 10. 松原要一, 佐藤信昭, 川島吉人ほか:進行癌患者の栄養管理と問題点. 癌治療と宿主1991;3:53-60.

• 11. Shaw JH, Humberstone DA, Douglas RG et al:Leucine kinetics in patients with benign disease, non-weight-losing cancer, and cancer cachexia;studies at the whole-body and tissue level and response to nutritional support. Surgery 1991;109:37-50.
  pubmed

• 12. Beck SA, Ground WP, Barton C et al:Alterlations in serum lipolytic activity of cancer patients with response to therapy. Br J cancer 1990;62:822-825.

• 13. Selberg O, Macmillian DC, Person T et al:Palmitate turnover and its response to glucose infusion in weight-losing cancer patients. Clinical Nutrition 1990;9:150-156.

• 14. Heber D, Tcheckmedyian NS:Cancer cachexia and anorexia. Nutritional Oncology (Herber D, Blackburn GL, W. Go Vay Ling eds.) Academic Press, San Diego, 1999, p519-536.

• 15. 標葉隆三郎, 西平哲郎:癌と免疫. 栄養免疫学 (渡辺明治編), 医歯薬出版, 東京, 1996, p188-192.

• 16. 漆崎一郎, 漆崎洋一:癌悪液質の概念と研究の変遷. 癌治療と宿主1990;1:15-24.

• 17. 漆崎一郎:癌悪液質の代謝異常とサイトカインネットワーク. 癌治療と宿主1996;8:39-48.

• 18. Oliff A:The role of tumor necrosis factor in cachexia. Cell 1988;54:141-142.
  pubmed

• 19. Moldawer LL, Grorgieff M, Lundholm K:IL-1, INF and pathogenesis of cancer cachexia. Clin Phisiol 1987;7:263-274.

• 20. Hoshino E, Picard C, Greenwood CE et al:Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Phsiol 1991;260:E27-36.

• 21. Dewys WD, Begg D, Lavin PT et al:Prognostic nutritional index in gastro-intestinal surgery. Am J Surg 1980;139:160-167.

• 22. Lundholm K, Edstorm S, Karlberg I et al:Relationship of food intake, body compotion and tumor growth to host metabolism in non-growing mice with sarcoma. Cancer Res 1980;40:2516-2522.

• 23. Van meyenfeldt MF, Visser G, Buil-Massen et al:Food intake and nutritional status in patients with newly detected gastric or colorectal cancer. Clinical Nutrition 1988;7:85-91.

• 24. Strassmann G, Fong H, Kenney JS et al:Evidence for the incolvement of interleukin 6 in experimental cancer cachexia.J Clin Invest 1992;89:1681-1684.

• 25. Matthys P, Dukmans R, Proost P et al:Severe cachexia in mice inoculated with interferon γ producing tumor cells. Int J Cancer 1991;49:77-82.

• 26. Ohe Y, Porack ER, Olsen KJ et al:Interleukin-6 cDNA transfected Lewes lung carcinoma cells show unaltered net tumor growth rate but cause weightloss and shorthen survival in synergenic mice. Br J Cancer 1993;67:939-944.

• 27. Sherry BA, Gelin J, Fong M et al:Anticachectin/TNF antibodies attenuate development of cachexia in tumor models. FASEB 1989;3:1956-1962.

• 28. Golin J, Moldwer LL, Lonnroth C et al:Role of endogeneous tumor necrosis factor α and interleukin-1 for experimental tumor growth and development of cancer cachexia. Cancer Res 1991;51:451-461.

P.131 掲載の参考文献

• 1. 岩佐正人, 小越章平, 田宮達男:外科患者の栄養療法. 消化器外科1988;11:711-719.

• 2. Vanek VW:The use of serum albumin as a prognostic or nutritional marker and the pros and cons of IV albumin therapy. Nutrition in Clinical Practice 1998;13:110-122.
  pubmed

• 3. Tavill AS, Craigie A, Rosenoer WM:The measurement of synthetic rate of albumin in man. Clin Sci 1968; 34:1-28.
  pubmed

• 4. Guthrie RD, Hines C:Use of intravenous albumin in criticalli ill patient. Am J Gastroenterol 1991;86:255-263.

• 5. Rothschild MA, Oratz M, Evans CD et al:Alteration in albumin metabolism after serum and albumin infusion. J Clin Invest 1964;43:1874-1880.

• 6. Erstad BL. Serum albumin concentrations. who need them?Ann Pharmacother 1992, 26:1134-1138.

• 7. Marik PE:The treatment of hypoalbuminemia in the critically ill patient. Heart Lung 1993;22:166-170.
  pubmed

• 8. Rothschild MA, Oratz M, Schreiber SS:Serum albumin. Hepatology 1988;8:385-401.
  pubmed

• 9. Deysine M:Albumin shifts across the extracelluar space secondary to experimental infections. S. G. O. 1980;151:617-620.

• 10. Buechter KJ, Byers PM:Nutrition and metabolism. In:(O'Leary JP, Capote LR, eds.) The physiological basis of surgery, 1st de. Baltimomore, Williams & Wilkins, 1993, p85-87.

• 11. 岩佐正人:食道癌患者の栄養評価に関する臨床的研究-特に栄養評価指数 (nutritional assessment index, NAI) の有用性について. 日本外科学会雑誌1985;84:1031-1041.

• 12. 岩佐幹恵, 岩佐正人, 小越章平:栄養評価の基礎. 検査と技術1997;25:250-254.

• 13. Golub R, Sorrento JJ Jr., Cantu R Jr. et al:Efficacy of albumin supplementation in the surgical intensive care unit:aprospective, randomized study. Cri Care Med 1994;22:613-619.

• 14. Reinhardt GF, Myscofski JW, Wilkens DB, et al:Incidence and mortality of hypoalbuminemic patients in hospitalized veterans. JPEN 1980;4:357-359.
  pubmed

• 15. Gales BJ, Erstad BL:Adverse reactions to human serum albumin.. Ann Pharmacother 1993;27:87-94.
  pubmed

• 16. Moyer ED, Border JR, Cerra FB et al:Multiple systems organ failure:IV. Imbalances in plasma amino acids associated with exogenous albumin in the traumaseptic patient. J Trauma 1981;21:543-547.

• 17. Alexander MR, Ambre JJ, Liskow BI et al:Therapeutic use of albumin. JAMA 1979;241:2527-2529.
  pubmed

• 18. Lucus CE, Ledgerwood AM, Higgins RF et al:Impaired pulmonary function after albumin resuscitation from shock. J Trauma 1980;20:446-451.

• 19. Grundmann R, Heistermann S:Postoperative albumin infusion therapy based on colloid osmotic pressure. A prospective randomized trial Arch Surg 1985;120:911-915.
  pubmed

第III章 疾患

P.143 掲載の参考文献

• 1.米田尚弘, 吉川雅則, 成田亘啓ほか:呼吸器疾患と栄養評価. 第22回日本医学会総会1987;II:248-249.

• 2. Yoneda T, Yoshikawa M, Tsukaguchi K et al:Nutritional assessment of chronic pulmonary diseases. In Nutrional Supportin Organ Failure. (Tanaka T, Okada A eds.), Elsevier Science Publishers, 1990, p165-p174.

• 3. 米田尚弘, 吉川雅則, 夫彰啓ほか:慢性閉塞性肺疾患:診断と治療の進歩, 栄養管理の意義. 日内会誌 1995;84:750-755.

• 4. 米田尚弘吉川雅則, 夫彰啓ほか:近畿地区COPDにおける栄養障害の頻度と病態生理の関連性. 日内会誌1994;83:121-122.

• 5. Wilson DO, Rogers RM, Wright EC et al:Body weight in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:1435-1438.
  pubmed

• 6. 夫彰啓, 米田尚弘, 吉川雅則ほか:慢性閉塞性肺疾患の予後因子としての体重. 呼吸1993;12:216-220.

• 7. 米田尚弘吉川雅則, 夫彰啓ほか:慢性閉塞性肺疾患の栄養免疫状態が予後におよぼす影響-予後栄養指数を用いた検討. 厚生省特定疾患呼吸不全調査研究班, 平成5年度研究報告書. 1994, p129-131.

• 8. 吉川雅則, 米田尚弘, 夫彰啓ほか:慢性閉塞性肺疾患患者における細胞性免疫能. 日胸疾会誌1994; 32:307-308.

• 9. Fuenzalada CE, Petty TL, Jones ML et al:The immune response to short-term nutritional intervention in advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;142:49-56.

• 10. Saher E:Dietary n-3 polyunsaturated fatty acid and smoking-related chronic obstructive pulmonary diseases. N Engl JJ Med 1994;331:228-230.

• 11. Palmer CE, Joblon S, Edwards PQ:Tuberculosis morbidity of young men in relation to tuberculin, sensitivity, and body build. Am Rev Tuber 1957;76:517-539.

• 12. 三上理一郎, 米田尚弘, 石橋純子ほか:結核疫学の諸問題, 結核発病の要因, 奈良県新登録患者調査から. 結核 1981;56:547-552.

• 13. 米田尚弘:肺結核での栄養障害と細胞性免疫能. 結核1989;10:39-46.

• 14. Yoneda T, Yoshikawa M, Tsukaguchi K et al:The relation between amino acid imbalance and cell mediated immunity. J Parent Ent Nutr 1989;13:21-25.

• 15. 米田尚弘, 江川信一, 吉川雅則ほか:肺癌患者の栄養評価. 肺癌1989;29:147-153.

• 16. 米田尚弘, 吉川雅則, 塚口勝彦ほか:肺癌患者におけるIL-2-NK細胞系と栄養障害の関連性. 呼吸 1994;13:76-80.
  Medical*Online

• 17. 米田尚弘, 吉川雅則, 塚口勝彦ほか:免疫・栄養スペクトル分類による肺癌患者の病態・予後予測の試み. 日胸臨1994;53:111-115.

• 18. Beutler B:Cachectin:More than a tumor necrosis factor. N Engl J Med 1987;316:379-384.
  pubmed

• 19. 塚口勝彦, 米田尚弘, 吉川雅則ほか:活動性肺結核における末梢血単球の1L-1およびTNF産生能と栄養障害の関連1生. 結核1991;66:477-484.

• 20. Yamamoto C, Yoneda T, Yoshikawa M et al:Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505-510.
  pubmed

• 21. Yoneda T:Nutritional assessment and support in chronic obstructive pulmoanry diseases. Proceeding of the 23rd Hakone Symposium, 1995, p3-P28.

P.149 掲載の参考文献

• 1. Marshall M, Kaplan:Laboratory Tests:In:Diseases ofthe liver. (Schiff L, Schiff ER, eds.) J. B. Lippincott Company, Philadelphia, 1993, p132-134.

• 2. Rothschild MA, Oratz M, Schreiber SS:Serum albumin. Hepatology 1988;8:385-401

• 3. Thurman RG, Kauffman FC:Sublobular compartmentation of pharmacologic events (scope):metabolic Huxes in periportal and pericentral regions of the liver lobule. Hepatology 1985;5:144-151.
  pubmed

• 4. Vaananen H, Lindros KO:Comparison of ethanol metabolism in isolated periportal or perivenous hepatocytes:effects of chronic ethanol treatment. Alcohol Clin EXp Res 1985;9:315-321.
  pubmed

• 5. Conway JG, Popp JA, Thurman RG:Microcirculation in periportal and pericentral regions of lobule in perfused rat liver. Am Physiol Soc 1985;249:G449-G456.

• 6. Vaananen H:Ethanol metabolism in periportal and perivenous rat hepatocytes isolated by collagenase gradient perfusion. Ph. D. Helsinki, Finland, 1986, p9-50.

• 7. Matsumura T, Kauffman FC, Meren H et al:O2 uptake in periportal and pericentral regions of liver lobule in perfused liver. Am J Physiol 1986;250:G800-G805.
  pubmed

• 8. Lloyd CE, Kalinyak JE, Hutson SM:Stimulation of albumin gene transcription by insulin in primary cultures of rat hepatocytes. Am J Physiol 1987;252:C205-C214.
  pubmed

• 9. Tavill AS, Craigie A, Rosenoer VM:The measurement of the synthetic rate of albumin in man. Clin Sci 1968;34:1-28.

• 10. Rothschild MA, Oratz M, Zimmon D et al:Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-C14.J Clin Invest 1969;48:344-350.

• 11. Salerno F, Badalamenti S, Incerti P et al:Repeated paracentesis and i. v. albumin infusion to treat tense ascites in cirrhotic patients. J Hepatol 1987;5:102-108.

• 12. Lieber CS:Alcohol, protein metabolism, and liver injury. Gastroenterology 1980;79:373-390.
  pubmed

• 13. Morland J, Bessesen A:Inhibition of protein synthesis by ethanol in isolated rat liver parenchymal cells. Biochim Biophys Acta 1977;474:312-320.
  pubmed

• 14. Lieber CS:Alcohol and the liver:1984 update. Hepatology 1984;4:1243-1260.
  pubmed

• 15. Villeneuve JP, Pomier G, Huet PM:Effect of ethanol on hepatic blood flow in unanesthetized dogs with chronic portal and hepatic vein catheterization, Can J Physiol Pharm 1981;59:598-603.

• 16. McKaigney JP, Carmichael FJ, Saldivia V et al:Role ofethanol metabolism in the ethano-induced increase in splanchnic circulation. Am J Physiol 1986;250:G518-G523.

• 17. Rothschild MA, Oratz M, Schreiber SS et al:The effects of ethanol and hyperosmotic perfusates on albumin synthesis and release. Hepatology 1986;6:1382-1385.
  pubmed

P.158 掲載の参考文献

• 1. Markri HH et al:Delimination and pathogenesis of clinically significant dys-proteinemias. Schweiz Med Wochenschr 1961;91:167-174.

• 2. 馬場忠雄ほか:病態別アミノ酸輸液. 内科領域. 最新アミノ酸輸液. (武藤輝一編) 医薬ジャーナル社, 東京, 1996, p231-244.

• 3. Blackburn GL:Nutritional and metabolic assessment of the hospitalized patients. JPEN J Parenter Enteral Nutr 1977;1:11-22.
  pubmed

• 4. 馬場忠雄:消化器疾患. 吸収不良症候群. 最新内科学大系. 中山書店, 東京, 1997;p271-281.

• 5. 馬場忠雄ほか:膜輸送蛋白異常症 吸収不良症候群. 日本臨床1996;54:782-787.

• 6. 馬場忠雄:タンパク漏出性胃腸症の診断基準・病型分類・重症度. 内科1995;1038-1041.

• 7. Crossley JR et al:Simple method for diagnosing protein-losing enteropathies. Br J Med 1997;1:428-429.

• 8. Florent C et al:Intestinal clearance of alpha 1-antitrypsin. A sensitive method for detection of protein-losing gastroenteropathy. Gastroenterology 1981;81:770-780.

• 9. Lichtsteine S et al:The interplay of DNA-binding proteins on the promoter of the mouse albumin gene. Cel 1987;51:963-973.

• 10. 辻中利政ほか:侵襲と遺伝子発現-侵襲時アルブミン遺伝子発現の制御機構. 医学のあゆみ1995;173:335-338.

• 11. Ramji DP et al:The two C/EBP isoforms, IL-6 DBP/NF-IL-6 and C/EBPδ/NF-IL6β, are induced by IL-6 to promote acute phase gene transcription via different mechanism. Nucleic Acids Res 1993;21:289-294.

P.170 掲載の参考文献

• 1. Bernard DB:Metabolic complications in nephrotic syndrome:Pathophysiology and complications. In:The Nephrotic Syndrome. (Brenner BM, Stein JH eds.) Churchill Livingstone, New York, 1982, p85.

• 2. Meyer TW, Baboolal K, Brenner BM:Nephron adaptation to renal injury. In:The Kidney. (Brenner BM ed.) Saunders, Philadelphia, 1996, p2011-2048.

• 3. Rothschild MA, Oratz M, Schreiber SS:Albumin synthesis. N Engl J Med 1972;286:748-757.
  pubmed

• 4. Waldmann TA:Albumin catabolism. In:Albumin Structure, Function and Use. (Rosemoer M, Oraz M, Roschild MA eds.) Pergamon, New York, 1977, p 255.

• 5. Kaysen GA, Gambertoglio J, Jimenez I et al:Effect of dietary protein intake on albumin homeostasis in nephrotic patients.Kidney Int 1986;29:572-577.
  pubmed

• 6. Yamauchi A, Imai E, Noguchi T et al:Albumin gene transcription is enhanced in liver of nephrotic rats. Am J Physiol 1988;254:E676-E679.
  pubmed

• 7. Katz J, Bonorris G, Sellers AL:Albumin metabolism in aminonucleoside nephrotic rats. J Lab Clin Med 1963;62:910-934.
  pubmed

• 8. Park CH, Maack T:Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 1984;73:767-777.

• 9. Sellers AL, Katz J, Bonorris G:Albumin distribution in the nephrotic rat. J Clin Lab Med 1968;71:511-516.

• 10. Kaysen GA, Jones H Jr, Martin V et al:Alow protein diet restricts albumin synthesis in nephrotic rats. J Clin In vest 1989;81:1623-1629.

• 11. Kaysen GA, Jones H Jr, Hutchison FN:High protein diets stimulate albumin syunthesis at the site of albumin mRNA transcription. Kidney Int 1989;36 (Suppl. 27):S168-S172.

• 12. Kaysen GA, Gambertoglio J, Jiminez I et al:Efffect of dieatry protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986;29:572-577.

• 13. Kaysen GA:The nephrotic syndrome:Nutritional consequences and dietary management. In:Handbook of Nutrition and the Kidney 3rd ed. (Mitch WE, Klahr S eds.) Lippincott-Raven, Philadelphia, 1998, p201-212.

• 14. Ideura T, Yoshimura A, Shimazui M:Efrect of very low protein diet in nephrotic syndrome. Wien Klin Wochenschr 1998;110 (Suppl. 4):21.

• 15. 血液製剤の使用指針 (厚生省), 1999.

• 16. Davison AM, Lamble AT, Verth AH et al:Salt-poor albumin in the management of nephrotic syndrome. Br Med J 1974;1:481-484.

• 17. 吉村吾志夫:アルブミン製剤. 内科1998;82:662-666.

• 18. 出浦照國, 吉村吾志夫:ネフローゼ症候群の対症療法. 腎炎・ネフローゼ, Common Disease Series 5 (長沢俊彦編) 南江堂, 東京, 1989, p153-t59.

• 19. Yoshimura A, Ideura T, Koshikawa S et al:Aggravation of minimal change nephrotic syndrome by administration of human albumin. Clin Nephrol 1992;37:109-114.
  pubmed

• 20. 吉村吾志夫, 出浦照國:ネフローゼ症候群におけるタンパクの負荷と制限, 腎と透析1997;42:481-485.

• 21. Cameron JS:Proteinuria and progression in human glomerular diseases. Am J Nephrol 1990;10 (Suppl):81-87.

• 22. Williams JD, Coles GA:Proteinuria:A direct cause of renal morbidity?Kidney Int 1994;45:443-450.
  pubmed

• 23. Eddy AA,. McCulloch L, Liu E et al:A relationship between proteinuria and zcute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 1991;138:1111-1123.

• 24. Nath KA, Hostetter MK, Hostetter TH:Pathophysiology of chronic tubulointerstitial disease in rats:Interactions of dietary acid load, ammonia and complement C3. J Clin Invest 1985;76:667-675.
  pubmed

• 25. Haws RM, Michel B:Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics 1993;91:1142-1146.

• 26. Leutscher JA, Hall AD, Kremer VL:Treatment of nephrosis with concentrated human serum albumin, II:effects on renal function and on excretion of water and some electrolytes. J Clin Invest 1950:29:896-904.

• 27. 横山和正:遺伝子組換えヒト血清アルブミン. 医学のあゆみ1991;159:481.

• 28. 医薬品としての遺伝子組換えアルブミン. 臨床分子医学1993;1:77-81.

• 29. 越川昭三, 太田善介, 出浦照國ほか:ネフローゼ症候群における浮腫に対するGB-1057(人血清アルブミン(組換え型)) の有効性, 安全性および有用性の検討(一般臨床試験). 臨床と研究1997;74:2900-2915.

P.180 掲載の参考文献

• 1. 山内邦男:人乳の成分. ミルク総合事典. (山内邦男, 横山健吉編) 朝倉書店, 東京, 1992, p68-72.

• 2. 長沢太郎ほか:人乳乳清蛋白質のアクリルアミドゲル電気泳動とゲル濾過による分画. 農化1970;44:89-95.

• 3. 土肥達:母乳のホエーたん白質について. Japanese J of Dairy and Food Science 1978;27:Al52-159.

• 4. Sturman JA, Gaull GE, Raiha NCR:Absence of cystathionase in human fetal liver:Is cystine essential? Science l 970;169:74-76.

• 5. Gaull GE, Sturman JA, Raiha NCR:Development of mammalian sulfur metabolism:Absence of cystathionase in human fetal tissue. Pediatr Res 1972;6:538-547.

• 6. 高瀬光徳, 島村誠一, 冨田守:ラクトフェリンの機能. 牛乳成分の特性と健康. (山内邦男, 今村経明, 守田哲朗編) 光生館, 東京, 1993;p85-109.

• 7. 川井裕介:健康人工栄養児の至適蛋白摂取量に関する研究. 第II編. 各種栄養法別健康乳児の血清蛋白及び血清非蛋白含量に就いて. 日児誌1965;69:426-435.

• 8. Fomon SJ:Protein:Seram concentration of albumin. In "Intant Nutrition (2nd Ed) ", Saunders, New york, 1974, p127-128.

• 9. 林康之:小児の血清蛋白分画値. 今日の小児診断指針. (前川喜平, 白木和夫, 土屋裕編) 医学書院, 東京, 1988, P467.

• 10. 滝田齊:血液生化学・機能検査, 肝, 小児の診断の進め方. (白木和夫, 美濃真編) 南江堂, 東京, 1992, p100-105.

• 11. 清水俊明:蛋白漏出性胃腸症. 小児内科1997増刊号 (小児疾患診療のための病態生理2) 1997;29:130-133.

P.190 掲載の参考文献

• 1. Gibson RS:Principles of nutritional assessment.-Assessment of protein status-. Oxford University Press, New York Oxford, 1990, p307-348.

• 2. Greenblatt DJ:Reducted serum albumin concentration in the elderly:A report from the Boston Collaborative Drug Survellance Program. J Am Geriatr Soc 1979;27:20-22.

• 3. Campion EW, deLabry LO, Glynn RJ:The effect of age on serum albumin in healthy males:Report from the Normative Aging Study. J Gerontol 1988;43:M18-M20.
  pubmed

• 4. Cooper JK, Gardner C:Effect of aging on serum albumin. J Am Geriatr Soc 1989;37:1039-1042.
  pubmed

• 5. Klonoff-Cohen H, Barrett-Conner E, Edelstein SL:Albumin levels as a predictor of mortality inthe healthy elderly. J Clin Epidemiol 1992;45:207-212.

• 6. Corti MC, Salive ME, Guralnik JM:Serum albumin and physical function as predictors of coronary heart disease mortality and incidence in older persons. J Clin Epidemiol 1996;49:519-536.

• 7. Corti MC, Guralnik JM, Sorkin JD:Serum albumin level and physical disability as predictors of mortality in old persons. JAMA 1994;272:1036-1042.

• 8. Ferguson RP, O'Conner P, Crabtree B et al:Serum albumin and prealbumin as predictors of clinical outcomes of hospitalized elderly nursing home residenrs. J Am Geriatr Soc 1993;41:545-549.

• 9. Corti MC, Salive ME, Guvalnk JM:Serum albumin and physical function as predictors of coronary heart disease mortarity and incidence in older persons. J Clin Epidemiol 1996;49:519-526.

• 10. Weijenberg MP, Feskens EJM, Souverijn JHM et al:Serum albumin, coronary heart disease risk, and mortality in an Elderly Cohort. Epidemiology 1997;8:87-92.

• 11. Sullivan DH, Walls RC:The risk of life-threatening complications in a select population of geriatric patients:the impact of nutritional status. J Am Coll Nutr 1995;14:29-36.

• 12. Phillips A, Shaper AG, Whincup PH:Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet 1989;2:1434-1436.
  pubmed

• 13. Young VR:Amino acids and proteins in relation to the nutrition ofelderly people. Age Ageing 1990;19:S10-24.

• 14. Baumgartner RN, Koehler KM, Romero L et al:Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr 1996;64:552-558.
  pubmed

• 15. 二木鋭雄:動脈硬化の新しいアプローチ-動脈硬化におけるoxidationの意義-. 動脈硬化update. (高久史麿監修) 中外医学社. 東京, 1992, p138-146.

• 16. Halliwell B:Albumin:an important extracellular antioxidant? Biochem Pharmacol 1988;37:569-571.
  pubmed

• 17. De Lorgeri M, Guidollet J, Renaud S:Serum albumin and mortality. Lancet 1990;335:349.

• 18. Grimble R:Serum albumin and mortality. Lancet 1990;335:350.

• 19. 広川勝呈:病態からみた栄養と免疫-老化-. 栄養免疫学. (渡辺明治編) . 医歯薬出版, 東京, 1996, p155-162.

• 20. 大荷満生:高齢者の免疫能. 臨床栄養. 1998;93:366-369.
  Medical*Online

• 21. Hedlund JU, Ortqvist AB, Kalin ME et al:Factors of importance for the long term prognosis after hospital treated pneumonia. Thorax 1993;48:785-789.

• 22. Hanson LC, Weber DJ, Rutala WA:Riskfactors for nosocomical pneumonia in the elderly. Am J Med 1992;92:161-166.

• 23. Riquelme R, Torres A, El-Ebiary M et al:Community-aquired pneumonia in the elderly, a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996;154:1450-1455.

第IV章 治療, 検査への応用

P.200 掲載の参考文献

• 1. 菅幹雄:無血清培養. 組織培養の技術 (第3版) 基礎編. (日本組織培養学会編) 朝倉書店, 東京, 1996, p70-72.

• 2. Block GD, Locker J, Bowen WC et al:Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF α in a chemically defined (HGM) medium. J Cell Biol 1996;132:1133-1149.

• 3. Yamane I, Murakami O, Kato M:Role of bovine albumin in a serum-free suspension cell culture medium. Proc Soc Exp Biol Med 1975;149:439-442.

• 4. 山根績:細胞増殖の生理. 最新組織培養応用研究法-In vitroアッセイと有用物質生産. (山根績ほか編) ソフトサイエンス社, 東京, 1985, p272-281.

• 5. Nilausen K:Role of fatty acids in growth-promoting effect of serum albumin on hamster cells in vitro. J Cell Physiol 1978;96:1-14.
  pubmed

• 6. Peters Jr T:Ligand binding by albumin. In:"All about Albumin:Biochemistry, Genetics, and Medical Applications". (Peters Jr T ed) Academic Press, San Diego, CA, 1996, p76-132.

• 7. Miyazaki M, Suzuki Y, Oda M et al:Improved maintenance of adult rat hepatocytes in a new serum-free medium in the presence or absence of barbiturates. In Vitro Cell Dev Biol 1989;25:839-848.
  pubmed

• 8. Chuniaud L, Dessante M, Chantoux F et al:Cytotoxicity of bilirubin for human fibroblasts and rat astrocytes in culture. Effect ofthe ratio of bilirubin to serum albumin. Clin Chim Acta 1996;256:103-114.

• 9. Diaz-Gil JJ, Gavilanes JG, Sanchez G et al:Identification of a liver growth factor as an albumin-bilirubin complex.Biochem J 1987;243:443-448.
  pubmed

• 10. Diaz-Gil JJ, Gavilanes JG, Garcia-Canero R et al:Liver growth factor purified from human plasma is an albumin-bilirubin complex. Mol Biol Med 1989;6:197-207.
  pubmed

• 11. Bian ZM, Elner VM, Lukacs NW et al:Glycated human serum albumin induces IL-8 and MCP-l gene expression in human corneal keratocytes. Curr Eye Res 1998;17:65-72.

• 12. Loban A, Kime R, Powers H:Iron-binding antioxidant potential of plasma albumin. Clin Sci (Colch) 1997;93:445-451.
  pubmed

• 13. Drouin R, Harvey P, Richer CL et al:Human serum albumin as a substitute for foetal calf serum in blast transformation assays and cytogenetic analyses. Cytobios 1987;52:193-207.
  pubmed

• 14. Wasik M, Gorski A, Nowaczyk M:An optimal assay of human B cell proliferation in vitro. J Immunol Methods 1987;99:1-5.

• 15. Bedotti R, Borghetti AF, Favilla R:Stimulatory efrect of serum albumin on the proliferation of serum-free SV40-transformed Balb/c 3T3 cells. Biochim Biophys Acta 1990;1053:74-80.

• 16. Ieki R, Kudoh S, Kimura H et al:Human granulocyte colony formation in serum-free cultures stimulated with purified recombinant granulocyte colony-stimulating factor. Exp Hematol 1990;18:883-887.
  pubmed

• 17. Agarwal DK, Chauhan LK:An improved chemical substitute for fetal calf serum for the micronucleus test. Biotech Histochem 1993;68:187-188.
  pubmed

• 18. Kiss C:Clonal growth and self-renewal of human myeloid leukemia cell lines (BRM and DD) in serumfree semi-solid culture. Blut 1990;61:317-319.
  pubmed

• 19. Kieler J, Skubis K, Grzesik W et al:Spreading of cells on various substrates evaluated by Fourier analysis of shape. Histochemistry 1989;92:141-148.
  pubmed

• 20. Schakenraad JM, Arends J, Busscher HJ et al:Kinetics of cell spreading on protein precoated substrata:A study of interfacial aspects. Biomaterials 1989;10:43-50.
  pubmed

• 21. Janecki A, Steinberger A:Experimental pitfalls in evaluating vectorial protein secretion in vitro; Sertoli cell secretion of androgen-binding protein and transferrin in two-compartment culture chambers. In Vitro Cell Dev Biol 1988;24:518-524.
  pubmed

• 22. Buset M, Winawer S, Friedman E:Defining conditions to promote the attachment of adult human colonic epithelial cells. In Vitro Cell Dev Biol 1987;23:403-412.
  pubmed

• 23. 宮崎正博ほか:ヒト肝細胞の初代培養とその応用. 癌と化学療法1992;19:1411-1419.

• 24. Miyazaki M, Namba M:Hepatocellular carcinomas. In "Atlas of Human Tumor Cell Lines". (Hay RJ et al eds) Academic Press, San Diego, CA, 1994, p185-212.

• 25. 川田雅昭ほか:ヒト肝由来細胞を利用したバイオ人工肝補助装置の開発-ラジアルフロー型バイオリアクターを用いて. Human Cell 1994;7:95-100.

• 26. 深谷憲一ほか:人工肝に利用する細胞-不死化細胞の利用. 組織培養工学1997;23:292-297.

P.211 掲載の参考文献

• 1. Ring J, Stephan W, Breddel W:Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production. Clinical Allergy 1979;9; 89-97.

• 2. Erstad BL:Viral infectivity of albumin and plasma protein fraction. Pharmacotherapy 1996;16 (6);996-1001.
  pubmed

• 3. 寮隆吉:ベッドサイドの新輸血学-効果的な輸血・輸液の実際-. メジカルビュー社, 東京, 1990, p12-18.

• 4. 高本滋:新鮮凍結血漿, アルブミン. 検査と技術増刊号1997;25:195-199.

• 5. 寮隆吉, 西郷勝康, 安永睦ほか:血漿分画製剤の特徴・適応と使い方:アルブミン, 輸血・血液製剤療法ガイド, Medical Practice臨時増刊号文光堂, 東京, 1992, p216-222.

• 6. 菊池修一:アルブミン製剤輸血. 臨床成人病1997;27:807-812.

P.219 掲載の参考文献

• 1. Maxam AM, Gilbert W:Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol 1980;65:499-560.
  pubmed

• 2. Lawn RM, Adelman J, Bock SC et al:The sequence of human serum albumin cDNA and its expression in E. coli. Nucleic A cids Res 1981;9:6103-6114.

• 3. 横山和正:遺伝子組換えヒト血清アルブミン. 医学のあゆみ1991;159:481.

• 4. 横山和正, 大村孝男:医薬品としての遺伝子組換えアルブミン. 臨床分子医学1993;1:77-81.

• 5. 大谷 渡, 真崎厚司, 池田義孝ほか:組換えヒト血清アルブミンの構造・組成分析. 薬学雑誌1997; 117:220-232.

• 6, 横山和正, 辰田武司:遺伝子組換えアルブミン-血漿分画製剤の国内自給達成に不可欠な手段. 医学のあゆみ1995;173:666-667.

• 7. 横山和正, 大村孝男:遺伝子工学によるアルブミンの生産. 日本アフェレシス学会雑誌1995;14:212-216.

• 8. 大村孝男:バイオテクノロジーによるヒト血清アルブミンの生産. バイオサイエンスとインダストリー 1995;53:507-509.

• 9. WHO Technical Report Series, 1987;No. 747.
  pubmed

• 10. 血清アルブミン. NIKKEI BIOTECHNOLOGY ANNUAL REPORT 19951995;486-487.

• 11. Ogata K, Nishikawa H, Ohsugi M:Ayeast capable of utilizing methanol. Argic Biol Chem 1969;33:1519-1520.

• 12. Cregg JM, Madden KR, Barringer KJ et al:Functional characterization of the two alcohol oxidase genes from the yeast Pichia pastoris. Mol Cell Biol 1989;9:1316-1323.
  pubmed

• 13. Ellis SB, Brust PF, Koutz PJ et al:Isolation of alcohol oxidase and two other methanol regulatable genes from the yeast Pichia pastoris. Mol Cell Biol 1985;5:1111-1121.
  pubmed

• 14. Couderc R, Baratti J:Oxidation of methanol by the yeast, Pichia pastoris. Purification and properties ofthe alcohol oxidase. Argic Biol Chem 1980;44:2279-2289.

• 15. Cregg JM, Barringer KJ, Hessler AY et al:Pichia pastoris as a host system for transformations. Mol Cell Biol l 985;5:3376-3385.

• 16. 血液行政のあり方に関する懇談会報告書, 厚生省医薬安全局血液対策課, 1997年12月12日.

• 17. 元木良一, 井上仁, 木暮道彦ほか:侵襲の大きな手術後の患者を対象とした遺伝子組換え人血清アルブミン (GB-1057) の一般臨床試験. 臨牀と研究1997;74:3162-3177.

• 18. 小柳仁, 八田光弘, 平田欽也ほか:開心術後の低アルブミン血症に対するGB-1057 (人血清アルブミン [組換え型]) の一般臨床試験. 臨牀と研究1997;74:3196-3208.

• 19. 太田宗夫, 山本保博, 寺田浩明ほか:熱傷受傷患者に対するGB-1057 L人血清アルブミン (組換え型) 」の一般臨床試験. 臨牀と研究1997;74:2928-2939.

• 20. 太田宗夫, 山本保博, 寺田浩明ほか:腸閉塞・急性膵炎などの急性腹症患者に対する遺伝子組換え人血清アルブミン (GB-1057) の一般臨床試験. 臨牀と研究1997;74:3149-3161.

• 21. 太田宗夫, 山本保博, 寺田浩明ほか:出血性ショックに対する遺伝子組換え人血清アルブミン(GB-1057)の一般臨床試験. 臨牀と研究1997;74:2916-2927.

• 22. 越川昭三, 太田善介, 出浦照國ほか:ネフローゼ症候群における浮腫に対するGB-1057 [人血清アルブミン (組換え型) ]の繰り返し投与時における有効性, 安全性および抗体産生の有無の検討. 臨牀と研究 1997;74:3138-3148.
  Medical*Online

• 23. 鎌田武信, 戸田剛太郎, 笠原彰紀ほか:肝硬変による腹水に対するGB-1057 [人血清アルブミン(組換え型)]の繰り返し投与試験. 臨牀と研究1997;74:3128-3137.

P.228 掲載の参考文献

• 1. 平山千里, 村脇義和, 堀立明:肝硬変にみられる病態-アミノ酸・蛋白代謝異常. 日本臨床 (増刊号) 1988;46:1108-1114.

• 2. 吉田貴, 加藤昌彦, 森脇久隆ほか:栄養療法の進歩-肝炎. 肝胆膵1989;19:33-37.

• 3. Dolz C, Raurich JM, Ibanez J et al:Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology l 991;100:738-744.

• 4. Launts HU, Selverg O, Korber J et al:Protein calorie malnutrition in liver cirrhosis. J Clin In vest 1992; 70:478-486.

• 5. Schneeweiss B, Graninger W, Ferenci P et al:Energy metabolism in patients with acute and chronic liver disease. Hepatology 1990;11:387-393.
  pubmed

• 6. Priijatmoko DWI, Strauss BJG, Lambert JR et al:Early detection of protein depletion in alcoholic cirrhosis:Role of body composition analysis. Gastroenterology 1993;105:1839-1845.

• 7. 橋本修, 吉田貴, 坂東哲朗ほか:肝疾患と栄養-慢性肝不全におけるアミノ酸栄養-. 医学のあゆみ 1982;120:466-473.

• 8. 鈴木一幸, 盛合理, 加藤章信ほか:肝硬変例におけるBCAA補給の栄養学的意義. JJPEN 1988;10:589-594.

• 9. 渡辺明治:栄養療法の進歩-肝硬変. 肝胆膵1989;19:41-48.

• 10. 鈴木一幸, 盛合理, 佐藤俊一:最近のアミノ酸療法-肝不全. JJPEN 1989;11:811-813.

• 11. Fischer JE et al:The effect of normalization of plasma amino acids on hepatic encephalopathy. Surgery 1976;80:77-91.
  pubmed

• 12. 武藤泰敏:肝不全用特殊組成アミノ酸輸液製剤:種類・成分比・投与法. 日本臨床1982;40:817-823.

• 13. 佐藤俊一, 鈴木一幸, 加藤章信ほか:神経伝達因子. 肝胆膵1984;8:649-654.

• 14. 市田文弘, 佐藤俊一, 柴崎浩一ほか:肝不全用経腸栄養剤SF1008Cの肝硬変患者における臨床評価. 肝胆膵1986;12:653-662.

• 15. 林茂樹, 青柳豊, 岡博ほか:肝性脳症治療用成分栄養剤ED-Hの比較臨床試験. JJPEN 1990;12:1267-1285.

• 16. 武藤泰敏, 吉田貴, 斉藤公志郎:肝硬変患者における肝不全用経調栄養剤SF-1008Cの栄養改善効果について. 肝胆膵1986;13:135-140.

• 17. 沖田美佐子ほか:肝硬変の栄養治療における分岐鎖アミノ酸補給. JJPEN 1986;3:13-19.

• 18. 武藤泰敏, 吉田貴, 山藤正広:慢性肝不全の栄養治療-分岐鎖アミノ酸補充療法をめぐって-. 日本医事新報1983;3101:3-9.

• 19. 武藤泰敏ほか:分岐鎖アミノ酸顆粒経口補充療法の低蛋白栄養状態に対する影響-クロスオーバー法による他施設検討. JJPEN 1989;11:995-.

• 20. 武藤泰敏, 吉田貴, 佐藤俊一ほか:肝硬変患者における分岐鎖アミノ酸顆粒BCAA-Gの用量反応性試験. JJPEN 1989;11:1119-1134.

• 21. 武藤泰敏, 吉田貴, 佐藤俊一ほか:肝硬変患者に対する分岐鎖アミノ酸顆粒BCAA-Gの臨床第三相試験. JJPEN 1989;11:1137-11564.

• 22. Mendenhall C, Bongiovanni G, Goldberg S et al:Changes in protein-calorie malnutrition associated with 30days of hospitalization with and without enteral nutritional therapy. JPEN 1985;9:590-596.

• 23. Swart GR, Frenkel M, van den BERG JWO:Minimum protein requirements in advanced liver disease:A metabolic ward study of the efrect of oral branched chain amino acid.In:Metabolic and Clinical Implications of Branched Chain Amino Acids and Ketoacids. (Walser M, Williamson JR eds.), Elsevier/North Holland, New York, 1981, p427-432.

• 24. Eriksson LS, Persson A, Wahren J:Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 1982;23:801-806.
  pubmed

• 25. Keohane PP, Attrill H, Grimble G et al:Enteral nutrition in malnourished patients with hepatic cirrhosis and acute encephalopathy. JPEN 1983;7:346-350.
  pubmed

• 26. Simko V:Long-term tolerance ofaspecial amino acid formula in patients with advanced liver disease. Nutr Rep Int 1983;27:765-773.

• 27. Sieg A, Walker S, Czygan et al:Branched-chain amino acid-enriched elemental diet in patients with cirrhosis of the liver. A double blind crossover trial. J Gastroenterol 1983;21:644-650.

• 28. McGee A, Henderson JM, Millikan WJ et al:Comparison of the effects of hepatic-Aid and casein modular diet of encephalopathy, plasma amino acids and nitrogen balance in cirrhosis patients. Ann Surg 1983; 197:288-293.

• 29. Fiaccadori F, Ghinell E, Pedretti G et al:Oral BCAA as nutritional supplementation in cirrhosis. In:Metabolism and Nutrition in liver disease. (Holm E, Kasper H eds.), MTP Press, Lancaster, 1984, p351-364.

• 30. Horst D, Norman DG, Conn HO et al:Comparison ofdietary protein with an oral branched chain-enriched amino acid supplement in chronic portal systemic encephalopathy:Arandomized controlled trial Hepatology 1984;4:279-287.

• 31. Christie ML, Sack DM, Pomposelli J et al:Enriched branched chain amino acid formula versus a casein based supplement in the treatment of cirrhosis. IPEN 1985;9:671-678.

• 32. Egberts AH, Schomerus H, Hamster W et al:Branched chain amino acids in the treatment of latent portsystemic encephalopathy. Gastroenterology 1985;88:887-895.

• 33. Fiaccadori F, Ellia GF, Lehndorff H et al:The efrect of dietary supplementation with branched-chain amino acids (BCAAs) vs. casein in patients with chronic recurrent port systemic encephalopathy. a controlled trial. In:(Soeters PB, Willson JHP, Meijer AJ eds.) Advances in ammonia metabolism and hepatic encephalopathy. Exerpta medica, Amsterdam, 1988, p487-497.

• 34. Cabre E, Gonzalez-Huix F, Abad-Lacruz A et al:Effect of total enteral nutrition on short-term outcome of severely malnourished cirrhotics. Gastroentrol 1990;98:715-720.

• 35. Marchesini G, Dioguardi FS, Bianchi GP et al:Long term oral branched chain amino acid treatment in chronic hepatic encephalopathy. A randomized double blind casein controlled trial. J Hepatol 1990;11:92-101.

• 36. Plauth M, Merli M, Kondrup J et al:ESPEN guidelines for nutrition in liver disease and transplantation. Clin ic Nutr 1997;16:43-55.

• 37. Morgan MY:Branched-chain amino acids in the management of chronic liver diseases Facts and fantasies. J Hepatol 1990;11:133-141.
  pubmed

• 38. Marchesini G:Nutritional treatment with BCAA in advanced liver cirrhosis. 日本消化器病学会雑誌1998; 95 (Suppl):106.

• 39. 市原明:分岐鎖アミノ酸の生化学-特に代謝の臓器特異性. JJPEN 1981;3:101-108.

• 40. Hayashi M, Ohnishi H, Kawade Y et al:Augmented utilization of branched chain amino acids by skeletal muscle in decompensated liver cirrhosis in special relation to ammonia detoxication. Gastroenterol Jap 1981;16:64-70.

• 41. Munro HN, Fernstrom D, Wurtman RJ et al:Insulin, plasma amino acid imbalance and hcpatic coma. Lancet 1975;1:722-724.

• 42. 佐藤俊一, 鈴木一幸, 加藤章信:慢性肝不全における血漿分枝鎖アミノ酸の減少の機序:ソマトスタチン によるインスリン抑制下の筋におけるアミノ酸・アンモニア代謝. 肝臓1985;26:1555-1557.

• 43. Yoshida T, Muto Y, Moriwaki H et al:Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn 1989;24:692-698.
  pubmed

• 44. 吉田貴, 武藤泰敏:肝硬変の予後からみたアミノ酸栄養. 日本臨床栄養学会誌1991;12 (2):3-9.

• 45. 佐藤俊一, 加藤章信, 鈴木一幸:特殊アミノ酸による肝不全の治療. カレントテラピー1986;4:1065-1073.

• 46. 加藤章信, 鈴木一幸, 和田玲子ほか:肝硬変の蛋白アミノ酸代謝異常とその対策. 消化器科1998;26:540-545.

• 47. 鈴木一幸, 加藤章信:肝硬変診療における最近の進歩:栄養治療(2)-栄養治療-. 肝胆膵フロンティア(3)肝硬変up-to-date. 診断と治療社, 東京, 1998, p132-138.

• 48. 三輪佳行, 白木亮, 加藤昌彦ほか:肝硬変患者における夜食によるエネルギー代謝改善効果に関する検討. 日消誌1998;95 (Suppl):259.

• 49. 鈴木一幸, 海藤勇, 佐藤俊一ほか:THF-Gの使用経験. THF研究会会報1983;5:19-24.

• 50. 加藤章信, 黒沢照男, 鈴木一幸ほか:THF-Gの投与量および投与方法に関する検討. THF研究会会報 1983;6:44-49.

• 51. 小松博道, 土井秀之, 中鉢誠司ほか:バリンの肝再生促進作用に関する基礎的検討. 肝臓1998;39 (Supp;.2):189.

• 52. 高橋仁志, 土井秀之, 里見進:バリンの肝細胞増殖効果の検討. 肝臓1998;39 (Suppl.2):190.

• 53. 松田佳子:アルブミン生合成のしくみとその異常. 血清アルブミン (青木幸一郎, 高木俊夫, 寺田弘編), 講談社, 東京, 1984, p161-186.

• 54. Jaffay H, Winzler RJ:The metabolism od serum proteins II. The effect of dietary protein on the turnover of rat serum protein. J Biol Chem 11958;231:111-116.

• 55. Rothschild MA, Oratz M, Mongelle J et al:Amino acid regulation of albumjn synthesis. J Nutr 1969;98:395-403.
  pubmed

• 56. Yap SH, Strair RK, Shairitz DA:Effect of a short term fast on the distribution of cytoplasmic albumin messenger ribonucleic acid in rat liver. J Biol Chem 11978;253:4944-4950.

• 57. Jefferson LS, Liao WSL, Peavy DE et al:Diabetes-induced alterations in liver protein synthesis. J Biol Chem 1983;258:1369-1375.

• 58. Kirsch R, Frith L, Black E et al:regulation of albumin synthesis and catabolism by alteration of dietary protein. Nature 1968;217:578-579.
  pubmed

• 59. Hoffenberg R, Gordon AH, Black EG et al:Plasma protein catabolism by the perfused rat liver Biochem J 1970;118:401-404.
  pubmed

• 60. Mortimore GE, Neely AN, Cox JR et al:Proteolysis in homogenates of perfused rat liver:Responses to insulin, glucagon and amino acids. Biochem Biophys Res Commun 1973;54:89-95.
  pubmed

• 61. Baynes JW, Thorpe SR:Identification of the sites of albumin catabolism in the rat. Arch Biochem Biophys 1981;206:372-379.
  pubmed

• 62. 盛合理:ラット灌流肝における芳香族アミノ酸代謝-分枝鎖アミノ酸の影響について-. 岩手医誌 1990;42:67-77.

• 63. Ferrando AA, Williams BD, Stuart CA et al:Oral branched-chain amino acids decrease whole-body proteolysis. JPEN 1995;19:47-54.

• 64. Montoya A, Gomez-Lechon MJ, Castel JV:Influence of branched-chain amino acids on the synthesis of plasma proteins by cultured rat hepatocytes. J Clin Nutr Gastroenterol 1987;2:117-125.

• 65. Okuno M, Moriwaki H, Kato M et al:Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin incultured rat hepatocytes. Biochem Biophys Res Commun 1995;214:1045-1050.

• 66. Usui T, Moriwaki H, Hatakeyama H et al:Oral supplementation with branched-chain amino acids improves transthyretin turnover in rats with carbon tetrachloride-induced liver cirrhosis. J Nutr 1996;126:1412-1420.
  pubmed

• 67. Kuwahata M, Oka T, Asagi K et al:Effect of branched-chain amino acids on albumin gene expression in the liver of galactosamine-treated rats. J Nutr Biochem 1998;9:209-214.

• 68. 小原啓彦, 桑波田雅士, 加藤章信ほか:四塩化炭素急性肝障害ラットにおけるアルブミン遺伝子発現の調節機序. 肝臓1995;36:289-295.

• 69. 岩崎雅行:血清アルブミン代謝の統一的把握. 日内会誌1966;55:22-35.

• 70. 湯本泰弘:1311アルブミンによる肝疾患のアルブミン代謝の検討. 日消誌1969;66:917-933.

• 71. 加藤昌彦, 吉田貴, 森脇久隆ほか:肝硬変患者の生体内アルブミン代謝動態に及ぼす経口分枝鎖アミノ酸 投与の影響. 肝臓1991;32:692-699.

• 72. May ME, Buse MG:Effects of branched-chain amino acids on protein turnover. Diabetes Metab Rev 1989; 5:111-132.

• 73. Goldberg AL, Odessey R:Oxidation of amino acids by diaphragm from fed and fasted rats. Am J Physiol 1972;223:1384-1391.
  pubmed

• 74. Buse MG, Biggers JF, Friderici KH et at:Oxidation of branched chain amino acids by isolated hearts and:diaphragm of the rats. The effect of fatty acids, glucose, and pyruvate respiration. J Biol Chem 1972;247:8085-8096.

• 75. Louard RJ, Barrett EJ, Gelfand RA:Overnight branched-chain amino acid infusion causes sustained suppression of muscte proteolysis. Metabolism 1995;44:424-429.
  pubmed

P.241 掲載の参考文献

• 1. Subcommittee of the Victorian Drug Usage Advisory Committee:Human albumin solutions:consensus statements for use in selected clinical situations. Med J Aust 1992;157:340-343.

• 2. Vermeulen LC, Ratko TA, Erstad BL et al:Aparadigum for consensus:The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med 1995;155:373-379.
  pubmed

• 3. Lasky LC, Finnerty EP, Genis L et al:Protein and colloidal osmotic pressure changes with albumin and/or saline replacement during plasma exchange. Transfusion 1984;24:256-259.
  pubmed

• 4. Guidet B, Luquel L, De Labriolle Vaylet C et al:Hemodynamic tolerance and plasma volume variations during plasma exchange. Int J Artif Organs 1987;10:325-330.
  pubmed

• 5. Fujii H:Plasma exchange using Dextran 40-electrolyte solution as the sole replacement fluid in malignant paraproteinemia. Transfusion 1988;28:42-45.
  pubmed

• 6. Owen HG, Brecher ME:Partial colloid replacement for therapeutic plasma exchange. J Clin Apheresis 1997;12:87-92.
  pubmed

• 7. Orlin JB, Berkman EM:Partial plasma exchange using albumin replacement:removal and recovery of normal plasma constituents. Blood 1980;56:1055-1059.
  pubmed

• 8. 峰島三千男:置換液アルブミン濃度設定法 (二重ろ過血漿交換法) . JSTP Vews 1990;No. 2 (autum):5.

• 9. Sinzinger H, Bednar J, Granegger S et al:LDL-apheresis and coccomitant ACE-inhibitor therapy. Atheros-clerosis 1994;105:115-116.

• 10. 塩川優一ほか:プラスマフェレーシスの実施状況と臨床的評価. 日本医事新報1985;3215:26-29.

• 11. Schmitt E, Kundt G, Klinkmann H:Three years with a national apheresis registry. J Clin Apheresis 1992;7:58-62.
  pubmed

• 12. Sutton DM, Nair RC, Rock G:Complications of plasma exchange. Transfusion 1989;29:124-127.
  pubmed

• 13. Huestis DW:Mortality in therapeutic heamapheresis. Lancet 1983;1:1043
  pubmed

• 14. Fell GS, Maharaj D:Trace metal contamination of albumin solutions used for plasma exchange. Lancet 1986;2:467-468.
  pubmed

• 15. Ring J, Messmer K:Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1997;1:466-469.

P.255 掲載の参考文献

• 1. Campbell RM et al:Behavior of 14C-and 131I-labelled plasma proteins in rat:Int J app Rad and Isotop 1956;1:66.

• 2. McFarlane AS:Labelling of plasma proteins with radioactive iodine. Biochem J 1956;62:135.
  pubmed

• 3. Sterling K:The turnover rate of serum albumin in man as measured by 131I tagged albumin. J Clin Invest 1951;30:1228.

• 4. Berson SA et al:Tracer experiments with 131I-labelled human serum albumin:distribution and degradation studies. J Clin Invest 1953;32:746.

• 5. Matthews CM:the theory of tracer experiments with 131I-labelled plasma protein. Phys Med Biol 1957;2:36.
  pubmed

• 6. 湯本泰弘:131 Iアルブミンによる肝疾患のアルブミン代謝の検討. 日消会誌1969;66:917.

• 7. 湯本泰弘:131 Iアルブミンと51CrアルブミンのDouble Isotope Methodによる肝疾患における消化管内蛋白漏出に関する検討. 日消会誌1969;66:934.

• 8. 岩崎雅行:血清アルブミン代謝の統一的把握. 日内会誌1966;55:22.

• 9. Lepage GA et al:Further studies on mechanism of action of 6-mercaptopurine. Cancer Res 1961;21:1590.
  pubmed

• 10. Mathews CM:Effects of plasmapheresis on albuminpools in rabbits. J Clin Invest 1961;40:603.

• 11. 大野文俊, 伊月豊度, 三好和夫:蛋白代謝面より見た蛋白漏出性胃腸症. 日消会誌1966;63:1303.

• 12. Gordon RS:Exdative enteropathy;abnormal permeability of the gastrointestinal tract demonstrable with labelled polyvinyl-pyrolidone. Lancet 1959;1:255.

• 13. Waldman TA:Gastrointestinal protein loss demonstrated by 51Cr-labelled albumin. Lancet 1961;2:121.

• 14. Rootwell K:direct intravenous injection of 51Cr-chromic-chloride compared with 125I-polyvinyl-pyrolidone and 131I-albumin in the detection of gastrointestinal protein loss. Scand J Clin Lab Invest 1966;18:405.

• 15. Waldman TA:Protein-loosing enteropathy. Gastroenterology 1966; 50:422.

• 16. Olarte JA:Fecal excretin of 131I labelled human serum albumin in liver cirrhosis. Gastroenterologia 1964;102:90

• 17. Jeejebhob KN, Coghill NF:The measurement ofgastrointestinal protein loss by a new method. Gut 1961;2:123.

• 18. Waldmann TA, Steinfeld JL, Dutcher TF et al:Role of gastro-intestinal system in"idiopathic hypoproteinemia". Gastroenterology 1961;41:197-207.
  pubmed

• 19. Grill BB, Hillemeier AC, Grybosky JD:Fecal α1-anti-trypsin clearance in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1984;3:56.

• 20. Divigi CH, Lisann NM, Yeh SDJ et al:Technetium-99m albumin SCintigraphy in the diagnosis of proteinloosing enteropathy. J Nucl Med 1986;27:1710-1712.

• 21. 柏木 徹, 福井弘幸, 上甲剛ほか:99m Tc標識アルブミンによるタンパク漏出性胃腸症のRIイメーギング診断. 核医学1990;27:1361-1367.

• 22. 玉木長良, 米倉義晴, 小西淳二ほか:テクネシウム人血清アルブミンD (99mTc) 注射液の第1相試験. 核医学1988;25:579.

• 23. Hildebrand P, Henze E et al:Localization ofenteral protein loss by 99m-technetium-albumin-scintipraphy. Eur J Nucl Med l 989;15:217.

• 24. Saverymuttu SH, Peters AM, Lavender JP et al:Detection of protein-loosing enteropathy by 1111n-transferrin scanning. Eur J Nucl Med 1983;8:40.

• 25. Aseem B, Ravi K, Udayp S et al:Diagnosing protein loosing enteropathy a new approach using Tc-99m human immunoglobulin. Clin Nucl Med 1995;20:969.

• 26. Aseem B, Deepar L et al:Scintigraphic diagnosis of protein loosing enteropathy using Tc-99m dextran. Clin Nucl Med 1995;20:1070.

P.264 掲載の参考文献

• 1. 井上正康, 岡嶋研二, 安東由喜雄ほか:無アルブミン血症. 代謝1985;22:35-46.

• 2. Inoue M, Hirata E, Morino Y et al:The role of albumin in the hepatic transport of bilirubin:studies in mutant analbuminemic rats. J Biochem (Tokyo) 1985;97 (3):737-743.
  pubmed

• 3. Inoue M, Okajima K, Nagase S et al:Plasma clearance of sulfobromophthalein and its interaction with hepatic binding proteins in normal and analbuminemic rats:is plasma albumin essential for vectorial transport of organic anions in the liver?Proc Natl Acad Sci U S A 1983;80 (24):7654-7658.
  pubmed

• 4. Inoue M, Koyama H, Nagase S et al:Hepato-renal transport of phenolsulfonphthalein in analbuminemic rats:albumin is essential for hepatic compensatory elimination of a nephrophilic ligand in animals with renal dysfunction. J Biochem (Tokyo) 1986;100 (1):201-206.
  pubmed

• 5. Inoue M, Okajima K, Itoh K et al:Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987;32 (2):198-203.
  pubmed

• 6. Ando Y, Inoue M, Hirota M et al:Effect of superoxide dismutase derivative on cold-induced brain edema. Brain Res 1989:477 (1-2):286-291.

• 7. Inoue M, Watanabe N:Targeting SOD by gene and protein engineering and inhibition of oxidative stress in various diseases. In "Antioxidants in Therapy and Preventive Medicine". (Emerit I and Packer L eds), Plenum Press, New York, 1990, pp5-12.

• 8. Hirota M, Inoue M, Ando Y:Inhibition of stress-induced gastric mucosal injury by a long acting superoxide dismutase that circulates bound to albumin.. Arch Biochem Biophys 1990;280 (2):269-273.
  pubmed

• 9. Hasuoka H, Sakagami K, Inoue M:Anew derivery type of superoxide dismutase improves the survival of swine warm ischemia-damaged transplanted liver. Transplant Proc 1989;50:164-165.

P.272 掲載の参考文献

• 1. Schechter DC, Nealon TF, Gibbon JH:Asimple extracorporeal device for reducing elevated blood ammonia levels. Surgery 1958;44:892-897.

• 2. Opolon P, Lavallard MC, Huguet C et al:Hemodialysis versus cross hemodialysis in experimental hepatic coma. Surg Gynecol Obest 1976;142 (6):845-853.

• 3. Chang TM:Haemoperfusios over microencapsulated adsorbent in a patient with hepatic coma. Lancet 1972;2 (7791):1371-1372.

• 4. Demetriou AA, Levenson SM, Novikofr PM et al:Survival, organization, and function of microcarrierattacched hepatocytes transplanted in rats. Proc Natl Acad Sci USA 1986;83 (19):7475-7459.

• 5. Sussman NL, Kelly JH:Extracorporeal liver support:cell-based therapy for the failing liver. Am J Kidney Dis 1997:30 (5 Supple. 4):S66-S71.

• 6. Ohshima N, Yanagi K, Miyoshi H:Packed-bed type reactor to attain high density culture of hepatocytes for use as a bioartificial liver. Artif Organs 1997;21 (11):1169-1176.
  pubmed

• 7. Kawada M, Nagamori S, Aizaki H et al:Massive culture of human liver cells in a newly developed radial flow bioreactor sysytem:ultrafine structure of functionally enhanced hepatocarcinoma cell lines. In vitro Cell Dev Biol 1998;34:109-115.

• 8. 蓮村 哲, 松浦知和, 相崎英樹ほか:ヒト由来肝細胞を用いたラジアルフロー型バイオリアクターによるアルブミン大量産生. 人工血液1997;5 (3):33-37.

• 9. te Velde AA, Flendrig LM, Ladiges NC et al:Immunological consequences of the use of xenogeneic hepatocytes in a bioartificial liver for acute liver failure. Int J Artif Organs 1997;20 (4):229-233.

• 10. Miyoshi H, Yanagi K, Fukuda H et al:Long-term performance of albumin secretion of hepatocytes cultured in a packed-bed reactor utilizing Porous resin. Articif Organs 1996;20 (7):803-807.

• 11. Peshwa MV, Wu FJ, Sharp HL et al:Mechanistics of formation and ultrastructural evaluation of hepatocyte spheroids. In Vitro Cell Dev Biol Animal 1996;32 (4):197-203.
  pubmed

• 12. 水谷悟:ラジアルフロー型バイオリアクター. 組織培養1992;18:249-254.

• 13. Jolly A, Desjardins JF, Fremond B et al:Survival, proliferation, and functions of porcine hepatocytes encapsulated in coated alginate beads:astep toward a reliable bioartificial liver. Transplantation 1997;63 (6):795-803.

• 14. Watanabe FD, Mullon CJ, Hewitt WR et al:Clinical experience with a bioartificial liver in the treatment of severe liver failure, A phase I clinical trial. Annals of Surg 1997;225:484-491

• 15. Gerlach JC:Long-term liver cell cultures in bioreactors and possible application for liver support. Cell Biol Toxicol 1997;13:349-355.
  pubmed